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SUMMARY 
 
Currently, there are nine known human herpesviruses and these viruses 
appear to have been a very common companion of humans throughout the 
millenia. Of human herpesviruses, herpes simplex viruses 1 and 2 (HSV-1, 
HSV-2), causative agents of herpes labialis and genital herpes, and varicella-
zoster virus (VZV), causative agent of chicken pox, are also common causes 
of central nervous system (CNS) infections. In addition, human 
cytomegalovirus (CMV), Epstein-Barr virus (EBV) and human herpesviruses 
6A, 6B, and 7 (HHV-6A, HHV-6B, HHV-7), all members of the herpesvirus 
family, can also be associated with encephalitis and meningitis. Accurate 
diagnostics and fast treatment are essential for patient recovery in CNS 
infections and therefore sensitive and effective diagnostic methods are 
needed. 
 
The aim of this thesis was to develop new potential detection methods for 
diagnosing of human herpesvirus infections, especially in immunocompetent 
patients, using the microarray technique. Therefore, methods based on 
microarrays were developed for simultaneous detection of HSV-1, HSV-2, 
VZV, CMV, EBV, HHV-6A, HHV-6B, and HHV-7 nucleic acids, and for HSV-
1, HSV-2, VZV, and CMV antibodies from various clinical samples.  
 
The microarray methods developed showed potential for efficiently and 
accurately detecting human herpesvirus DNAs, especially in CNS infections, 
and for simultaneous detection of DNAs or antibodies for multiple different 
human herpesviruses from clinical samples. In fact, the microarray method 
revealed several previously unrecognized co-infections.  
 
The microarray methods developed were sensitive and provided rapid 
detection of human herpesvirus DNA, and therefore the method could be 
applied to routine diagnostics. The microarrays might also be considered as 
an economical tool for diagnosing human herpesvirus infections.   
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TIIVISTELMÄ (SUMMARY IN FINNISH) 
 
Herpesvirukset ovat kulkeneet ihmisen kumppaneina vuosituhat toisensa 
jälkeen ja tällä hetkellä tunnetaan yhdeksän ihmiselle patogeenista 
herpesvirusta. Huuli- ja genitaaliherpestä aiheuttavat herpes simplex virus 1 
ja 2 (HSV-1, HSV-2) sekä vesirokkoa aiheuttava varicalla-zoster virus (VZV) 
ovat ihmisen herpesviruksia, jotka voivat aiheuttaa myös vakavia 
keskushermostoperäisiä infektioita. Ihmisen herpesviruksista myös ihmisen 
cytomegalovirus (CMV), Epstein-Barr virus (EBV), ihmisen herpesvirukset 6 
ja 7 (HHV-6, HHV-7), voidaan liittää aivokuumeeseen ja 
aivokalvontulehdukseen. Näiden virusten nopea ja tarkka diagnostiikka on 
oleellista oikean hoidon aloittamiselle sekä potilaan toipumiselle varsinkin 
keskushermostoperäisissä infektioissa. Taudinaiheuttajien diagnosoimiseksi 
tarvitaan herkkiä ja tehokkaita menetelmiä. 
 
Tämän väitöskirjan tavoitteina oli kehittää uusia mikrosirupohjaisia 
menetelmiä ihmisen herpesvirusten aiheuttamien infektioiden 
diagnostiikkaan. Kehitetyillä mikrosiruilla tunnistettiin yhtä aikaa 
kahdeksan eri herpesviruksen nukleiinihappoa erilaisista kliinisistä 
näytteistä. Toisella serologisella mikrosirulla detektoitiin HSV-1, HSV-2, VZV 
ja CMV:lle spesifisiä vasta-aineita.  
 
Herpesvirusten nukleiinihappojen ja vasta-aineiden tunnistamiseen 
kehitetyt mikrosirumenetelmät osoittautuivat soveltuviksi usean 
herpesviruksen samanaikaiseen diagnosointiin. Varsinkin 
keskushermostopohjaisten infektioiden tunnistamisessa mikrosiru 
osoittautui tehokkaaksi. Mikrosirujen avulla tunnistettiin myös mahdollisia 
useamman viruksen samanaikaisia infektioita.  
REVIEW OF THE LITERATURE 
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1. HUMAN HERPESVIRUSES  
 
The tendency of herpesviruses to “creep” and spread is reflected in their 
name herpes, which comes from the Latin word herpes which, in turn, 
comes from the Greek word herpein, meaning to creep. The herpesvirus 
family is a large family of DNA viruses that cause diseases in humans and 
animals. Over 100 herpesviruses have already been isolated, and to date, 
there are nine known human herpesviruses [Strauss & Strauss 2002; 
Büchen-Osmond 2007].  
 
The family Herpesviridae is divided into three subfamilies: 
Alphaherpesvirinae, Betaherpesvirinae, and Gammaherpesvirinae. Human 
herpesviruses 1 and 2 (HHV-1, HHV-2; also known as herpes simplex 
viruses or HSVs) belong to the genus Simplexvirus, and human herpesvirus 
3 (HHV-3; also known as varicella-zoster virus, VZV) to the genus 
Varicellovirus, both members of the Alphaherpesvirinae subfamily. Human 
herpesvirus 5 (HHV-5; also known as human cytomegalovirus, HCMV or 
CMV) belongs to the genus Cytomegalovirus, and human herpesviruses 6A, 
6B and 7 (HHV-6A, HHV-6B, HHV-7) belong to the genus Roseolovirus, both 
members of Betaherpesvirinae subfamily. Human herpesvirus 6 can be 
divided in two different variants: HHV-6A and -6B. Of these two different 
strains, HHV-6A shows more neurotropism than HHV-6B. Human 
herpesvirus 4 (HHV-4; also known as Epstein-Barr virus, EBV) and human 
herpesvirus 8 (HHV-8) belong to the Gammaherpesvirinae subfamily 
[Strauss & Strauss 2002; McGeoch, Rixon & Davison 2006; Büchen-Osmond 
2007].   
 
First breakthrough in herpesvirus characterization was in the early 20th 
century [Goodpasture 1929; Goodpasture 1942]. The first published 
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descriptions of elementary bodies of herpes simplex virus were made, and in 
1949 electron microscopy of HSV was performed and the reactivation of HSV 
was suggested [Blank & Brody 1950; Coriell & Rake 1950]. VZV was isolated 
from the vesicular fluid of both chickenpox and zoster lesions in cell culture 
by T.H. Weller in early 1950 [Weller & Witton 1958]. CMV was observed and 
isolated by several scientists: T.H. Weller, M.G. Smith, and W.P. Rowe, in 
1956-57 [Harnden et al. 1967; Ho 2007]. Epstein-Barr virus was named 
after Tony Epstein and Yvonne Barr, who first isolated EBV from Burkitt´s 
lymphoma samples in 1964 [Epstein, Achong & Barr 1964]. HHV-6 was 
discovered in 1986 and HHV-7 shortly thereafter in 1990 [Salahuddin et al. 
1986; Frenkel et al. 1990]. HHV-8 was discovered by Chang and Moore in 
1994-95 and was linked to malignancies, especially Kaposi’s sarcoma [Moore 
et al. 1996].   
 
1.1. Structure and genome 
 
The mature herpesvirus virion consists of an envelope, a tegument, a 
nucleocapsid, and a core [Roizman & Pellett 2001; Strauss & Strauss 2002; 
McGeoch, Rixon & Davison 2006; Büchen-Osmond 2007]. In general, 
herpesviruses are spherical to pleomorphic, and 120-200 nm in diameter. 
The surface of the virion is evenly covered with spikes that are distributed 
densely and can be seen as distinctive surface projections. The outermost 
part of the virion is an envelope which is a lipid bilayer containing viral 
glycoproteins and lipids that are of host cell origin. These lipids are derived 
during budding from the nuclear or other host cell membranes. The 
tegument layer is located between the envelope and capsid, and its proteins 
are present in variable amounts and arranged in a sometimes asymmetric 
manner. The capsid or nucleocapsid exhibits icosahedral symmetry (T=16) 
and appears round. The diameter of the capsid varies from 115 to 130 nm. 
The capsids consist of 162 capsomers and arrangement is visible in electron 
microscopy. The genome is a single molecule of linear double-stranded DNA 
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varying from 124-235 kbp, and it is wrapped around the core, which 
consists of a fibrillar reel. The core, with the DNA, is located inside the 
capsid shell, which is then called a nucleocapsid. The ends of the core fibers 
are anchored to the capsid shell. The viral genome encodes structural and 
non-structural proteins of the envelope, tegument and capsid. DNA 
molecules contain regions of unique sequence flanked by direct or inverted 
repeats [McGeoch, Rixon & Davison 2006].  
 
1.2. Replication 
 
In general, herpesvirus virions attach to the host cell by binding to 
glycosaminoglycans on the surface of the cell [Trybala et al. 1993; Roizman 
& Knipe 2001; Spear & Longnecker 2003]. For alpha- and 
gammaherpesviruses, binding can be mediated by a virion glycoprotein that 
is not required for entry. For example, glycoprotein gC for HSV and gp350 for 
EBV (in the case of B cells) are ligands for binding to cellular receptors of 
heparin sulfate and complement receptor 2, respectively.   
 
The three glycoproteins gB, gH and gL are thought to be essential for the cell 
entry of all herpesviruses. In addition, gD and gp42 are proposed to be 
ligands for fusion for HSV and EBV, respectively [Spear & Longnecker 2003; 
Rey 2006]. For HSV, cellular receptors for fusion are, e.g., herpesvirus entry 
mediator (HVEM), which belongs to the tumor necrosis factor receptor 
family, and nectin-1 and -2, members of the immunoglobulin family.  After 
binding, the viral envelope fuses to the cell plasma or endosomal membrane 
and the nucleocapsid of the virus enters the cytoplasm.   
 
The nucleocapsid travels using the cytoskeleton of the cell to access the 
nucleus [Cohen & Straus 2001; Roizman & Knipe 2001; Garner 2003]. The 
capsid releases the linear viral DNA through nuclear pores into the nucleus. 
REVIEW OF THE LITERATURE 
 Microarrays in Human Herpesvirus Diagnostics - 13 
The viral DNA then circularizes and the cellular RNA polymerase transcribes 
the viral DNA into mRNA [Cohen & Straus 2001; Roizman & Knipe 2001; 
Strauss & Strauss 2002]. Viral gene expression is regulated and can be 
divided in three steps. First, transcription of immediate-early (IE) genes, 
which generally encode regulatory proteins, is activated. The IE-proteins 
initiate the transcription of early genes encoding enzymes which are needed 
to increase the amount of nucleotides and for viral replication. The control of 
transcription is dependent both on the cell´s nuclear factors and proteins 
encoded by the virus. This system determines whether the infection will 
result in production of new virus particles and cell death (a lytic infection), 
persistent shedding of viruses (a persistent infection) or latency. 
Herpesviruses encode their own DNA polymerase, and some herpesviruses 
encode enzymes (such as thymidine kinase) that allow the virus to grow in 
non-dividing cells that do not therefore contain the precursors of DNA 
synthesis. Neurotropic herpesviruses cannot efficiently replicate without 
thymidine kinase (a phosphotransferase which can be found in most of the 
living cells) in nerve cells due to the low amounts of certain DNA precursors. 
 
Finally, late genes, which encode the viral structural proteins, are activated 
and transcribed [Cohen & Straus 2001; Roizman & Knipe 2001; Mettenleiter, 
Klupp & Granzow 2006]. The transcription takes place in the nucleus, from 
which the mRNA is transferred to the cytoplasm to be translated into 
proteins. Depending on the protein, they can either go back into the nucleus, 
stay in the cytoplasm, or be transferred to the cell membrane, where they 
are incorporated. In the nucleus, the viral capsid proteins start to assemble 
and to form empty capsids. The full-length viral genome is copied and 
packaged into capsids to form nucleocapsids. Part of the nuclear membrane 
of the cell is covered with e.g. glycosylated proteins that trigger budding of 
nucleocapsid through the nuclear membrane. The nucleocapsid binds to this 
area and is budded to the cytoplasm. In the cytoplasm, the nucleocapsids 
are trapped by viral tegument proteins. At the final envelopment site of the 
endoplasmic reticulum, viral glycoproteins and outer tegument proteins 
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come together, and when the nucleocapsid with tegument proteins arrives 
there, accumulation begins and the final envelope is formed. Mature virions 
are then released by exocytosis. 
 
1.3. Epidemiology and transmission 
 
Generally, all human herpesviruses can spread via body fluids such as 
saliva. Herpesviruses which are latent in immune defense cells, e.g. CMV, 
EBV, HHV-6 and HHV-7, may also spread via transplantation. HSVs spread 
from person-to-person in close contact situations, for example, through 
blisters or lesions on skin or mucosa and also during sexual contact. VZV 
spreads via both contact and respiratory routes. EBV spreads via saliva, and 
CMV via several different routes, e.g. saliva, but also breast milk, body 
fluids, direct contact, blood transfusions and transplantation [Garner 2003; 
Hukkanen et al. 2003; Vetsika & Callan 2004; Ho 2007.].   
 
Generally, it can be said that human herpesviruses have been a very 
common companion of humans throughout the millenia. Nowadays, 
seroprevalences of human herpesviruses are surprisingly high, even though 
the state of hygiene, and residential density have changed within recent 
decades. Geographic location, changes in sexual behavior, child daycare, 
and breast-feeding may also have an influence on seroprevalence [Hukkanen 
et al. 2003; Svahn et al. 2006].      
 
In Finland, HSV seroprevalence has been estimated to be currently about 
50% among adults [Hukkanen et al. 2003; Alanen et al. 2005]. HSV-1 
infection is more common than HSV-2 infection. A seroprevalence for VZV of 
over 80% has been calculated for Finnish children, and the percentage has 
been shown to increase to over 95% in adults [Aarnisalo et al. 2003; Nardone 
et al. 2007]. The CMV seroprevalence rises along with age and varies from 
55% to 80% in adults in Finland. EBV infections are acquired during 
REVIEW OF THE LITERATURE 
 Microarrays in Human Herpesvirus Diagnostics - 15 
childhood and adoscelence, and seroprevalences of up to 90% have been 
estimated for adults in Finland. The seroprevalence for HHV-6 worldwide is 
over 90% and the infection is acquired during early childhood [Okuno et al. 
1989].  
 
1.4. Pathogenesis  
 
1.4.1. Primary infection 
 
All herpesviruses have primary target cells which they most efficiently infect. 
These target cells are often part of transmission routes. Mucoepithelial cells 
are primary targets of HSV-1, HSV-2, and VZV, which are all 
alphaherpesviruses [Garner 2003]. Several other cell types are preferred by 
betaherpesviruses, e.g. T lymphocytes for HHV-6 and -7 [De Bolle et al. 
2005; Miyake et al. 2006], and epithelia, lymphocytes, or monocytes for CMV 
[Hummel & Abecassis 2002; Jarvis & Nelson 2002; Sinclair & Sissons 2006]. 
EBV, which is a gammaherpesvirus, can efficiently infect epithelial cells and 
B lymphocytes [Amon & Farrell 2005]. After replication of HSV-1 or -2 in the 
oral or genital mucosa, there is an uptake of virus into sensory nerve fibers 
followed by retrograde microtubule-associated transport to the cell body of 
neurons in the dorsal root ganglion near the spinal cord or into the 
trigeminal ganglion [Cunningham et al. 2006]. There the virus lapses into 
the latent state. 
   
Symptoms of primary infection vary among herpesviruses. Tiny blisters 
called vesicles are commonly form around the mouth and nose (“cold sores”) 
due to HSV-1 infection, and in the genital area, most commonly as a result 
of HSV-2 infection. However, the epidemiology of the genital herpes is 
changing with evidence which indicate an increasing incidence of HSV-1 
infections, particularly in young women 30 years of age or less [Ribes et al. 
2001; Forward & Lee 2003]. VZV infection starts with symptoms of the 
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common cold, continuing with vesicle formation on various parts of the body 
(chicken pox) [reviewed in Garner 2003, and Hambleton & Gershon 2005]. 
Classic fever, pharyngitis and lymphadenopathy (throat pain and swollen 
lymph glands) are symptoms of mononucleosis, resulting from EBV 
infections [Kieff & Levine 1974; Vetsika & Callan 2004]. Occasionally, CMV, 
HHV-6, and HSV may cause mononucleosis-like illnesses [Hurt & Tammaro 
2007]. EBV is also associated with post-transplant lymphoproliferative 
disorders (PTLD) and malignancies such as Burkitt´s lymphoma and 
nasopharyngeal carcinoma [Kieff & Levine 1974; Kieff 1995; Preiksaitis & 
Keay 2001; Junker 2005]. Roseola (also known as sixth disease, exanthema 
subitum, or roseola infantum) is a disease caused by HHV-6, and 
occasionally HHV-7 [Yamanishi et al. 1988].  
 
In general, the severity of the primary infection depends on the immune 
status (immunocompetent vs. immunodeficient) and the age of the person. 
Symptoms of herpesvirus infections that occur during childhood are typically 
milder than in adolescence or adulthood. The primary infection, however, 
can also be asymptomatic, especially in children.  
 
1.4.2. Latency and reactivation 
 
Herpesviruses can evade or confuse the immune system so that it does not 
“clean” these viruses from the body and they can enter a latent state after 
primary infection and reactivate from this state. Different events, e.g. 
transplantation, cancer, infection, stress or other health conditions that 
lower the body´s defenses, can trigger the reactivation of latent 
herpesviruses.  
 
Alphaherpesviruses, HSVs and VZV establish a latent state in neurons [Hill 
et al. 1990; Whitley 2001; Kennedy 2002; Efstathiou & Preston 2005; 
Steiner, Kennedy & Pachner 2007]. Betaherpesviruses, HHV-6 and HHV-7 
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switch from primary infection to latent state in T lymphocytes [De Bolle et al. 
2005; Miyake et al. 2006] and CMV converts to latency in monocytes, 
lymphocytes and possibly other cell types [Hummel & Abecassis 2002; Jarvis 
& Nelson 2002; Sinclair & Sissons 2006]. In addition, HHV-6 is the only 
human herpesvirus known to integrate into host chromosome [Torelli et al. 
1995; Daibata et al. 1999]. EBV, a gammaherpesvirus, establishes a latent 
state in B lymphocytes [Amon & Farrell 2005]. CMV reactivation results in 
serious morbidity and mortality in immunocompromised transplant 
recipients and reactivation has been suggested to be a multi-step process 
initiated by the response to the transplanted organ [see review Hummel and 
Abecassis 2002]. 
 
The immune system treats the neurons somewhat differently than other cell 
types. The ability to achieve latency in neuronal cells allows the maintenance 
of HSV for the lifetime of the host [Roizman & Knipe 2001; Whitley 2001; 
Garner 2003].  
 
2. CLINICAL MANIFESTATIONS 
 
Herpesviruses cause a wide variety of diseases. For HSVs the symptoms of 
reactivated infection are quite similar to those of primary infection and 
reactivations often occur. HSV-1 reactivations causing “cold sores” recur 
multiple times whereas, for example, VZV reactivation is not usually 
recurrent. In the case of VZV reactivation, the symptoms differ from those of 
a primary infection and the rate of occurrence is much lower than with 
HSVs. VZV causes herpes zoster, commonly known as shingles. It is most 
common in elderly, and causes lesions, nerve pain and occasionally small 
vesicles on the skin surface at the nerve ends. Post herpetic neuralgia (PHN), 
i.e., sustained nerve pain, is more frequent in the elderly, probably because 
of impaired cell-mediated immunity to VZV [Hambleton & Gershon 2005; 
Dworkin et al. 2008]. VZV reactivation tends to occur with increasing age 
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whereas HSV-1 reactivations tend to decrease with age [Steiner, Kennedy & 
Pachner 2007]. Zoster may cause abnormalities or complications of the 
central nervous system (CNS), i.e. mild mononuclear pleocytosis with a slight 
increase in protein levels. In general, all the human herpesviruses can also 
cause severe or even life-threatening diseases, e.g. CNS infections, which are 
fortunately not very common.  
 
2.1. Central nervous system infections 
 
Encephalitis, an acute inflammation of the brain, and meningitis, an acute 
inflammation of the protective membranes covering the CNS, are life-
threatening diseases [Whitley 2006; Kovanen 2007a; Kovanen 2007b]. 
Encephalitis is often meningoencephalitis, where the inflammation has 
spread from the protective membranes to the brain. Myelitis, in which the 
CNS functions linking the brain and limbs are disrupted by swelling of the 
spinal cord, is also a severe disease. Of the herpesviruses, HSV, VZV and 
CMV are the most common causes of these life-threatening diseases, but 
EBV and HHV-6 can also be associated with encephalitis and meningitis 
[Aberle & Puchhammer-Stöckl 2002; Whitley 2006; Gilden et al. 2007; 
Mannonen et al. 2007]. HHV-7 has also been suspected to cause 
encephalitis but is not often looked for as a causative agent [Calvario et al. 
2002; Ward et al. 2002]. Herpesviruses can also cause acute or chronic 
lymphocytic meningitis [Peltola & Valtonen 2003; Kupila et al. 2004].  
 
The incidence of viral encephalitis is about 3/100 000 per year in Finland, 
and the main causes are HSV, VZV, and, particularly in the coastal regions 
of Finland, tick-borne encephalitis viruses (TBEV) [Koskiniemi et al. 2001; 
Hukkanen & Vuorinen 2002; Kupila et al. 2006; Kovanen 2007a; Kovanen 
2007b]. Herpes simplex encephalitis (HSE) is a very severe infection of the 
CNS [reviewed by Whitley 2006]. Symptoms and signs of encephalitis can 
include fever, fatigue, headache, lethargy, irritability, confusion, 
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hallucinations, epileptic seizures, dysphasia, aphasia, and problems of 
cognition [Whitley 2006; Gilden et al. 2007; Kovanen 2007b]. These signs 
and symptoms reflect virus replication with accompanying inflammation in 
the medial temporal lobe and orbital surface of the frontal lobe. Mortality can 
be up to 70% without proper antiviral treatment. Mortality decreases to 
~20% with treatment, and 50-60% of patients recover well or reasonably 
well. Survivors can be left with permanent seizure disorders, mental status 
changes, aphasia or motor deficits [Gilden et al. 2007]. In Finland, VZV has 
been suggested to be a major causative agent in CNS infections, followed by 
HSV and TBEV [Koskiniemi et al. 2001; Kupila et al. 2006]. VZV is also 
known to cause encephalitis in children after chickenpox and these 
symptoms occur typically 2-4 weeks after the onset of primary symptoms 
[Kovanen 2007b].  
 
Viral meningitis is more common than bacterial meningitis. It is most often 
caused by enteroviruses, especially coxsackie and echoviruses, but other 
viruses, like HSV and VZV, can also be causative agents [Koskiniemi et al. 
2001; Kupila et al. 2006; Kovanen 2007a]. The occurrence of viral meningitis 
is usually highest at the end of summer and beginning of autumn in Finland 
[Hukkanen & Vuorinen 2002]. Fever, headache, nausea and vomiting, 
stiffness of the neck, and problems with cognition can be symptoms of viral 
meningitis [Peltola & Valtonen 2003]. There is no antiviral treatment for 
enteroviral meningitis. For meningitis caused by herpesviruses, antiviral 
drugs can be administered. Patients usually recover well, and meningitis is 
considered to be less severe than encephalitis. However, meningitis can turn 
into encephalitis, and therefore patients have to be examined and monitored 
carefully.  
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2.2.  Facial palsy 
 
Herpesviruses, especially VZV, HSV and HHV-6, have been suggested to be 
associated with facial palsy (FP) [Furuta et al. 2005; Kanerva et al. 2007; 
Pitkäranta et al. 2000; Pitkäranta, Lahdenne & Piiparinen 2004]. HSV-1 and 
VZV are considered possible etiologic factors for idiopathic peripheral facial 
palsy (Bell’s palsy, BP), and VZV for Ramsay Hunt syndrome (RHS) [Furuta 
et al. 2005; Gilden et al. 2007; Murakami et al. 1998]. BP and RHS can 
present either in mononeuritic or polyneuritic forms, and occasionally 
inflammatory CSF findings are observed in BP patients, suggesting a CNS 
infection. FP is considered by some to be a result of CMV infection or in rare 
cases, EBV infection [Furuta et al. 2005].  
 
Herpesvirus reactivation, rather than primary infection, is most often 
associated with FP [Mori, Nagai & Asanuma 2002; Furuta et al. 2005; Gilden 
et al. 2007]. In BP, the facial muscles are weakened or become paralyzed. 
This condition is not permanent and approximately half of BP patients will 
have essentially complete recovery in a short time. BP and RHS share most 
of the same symptoms. Pain, often in or behind the ear, can be acute and is 
one of the symptoms. It can start before muscle weakness is apparent and 
last a week or two, and with RHS even longer. Dizziness is another symptom 
that BP and RHS share. Hearing loss and blisters in the ear have been 
reported with RHS but not with BP. Vesicles is often the only clearly visible 
symptom that identifies RHS. BP is not contagious but RHS is when shingles 
vesicles are present.  
 
There is another rare neurological disorder, Melkersson-Rosenthal syndrome 
appearing in childhood or early adolescence, which is characterized by, 
among other things, recurring facial paralysis and swelling of the face and 
lips [Ziem et al. 2000].  
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2.3. Treatment and antiviral drugs 
 
Nucleoside analogs are the largest group of antiviral drugs which have been 
used to treat herpesvirus infections [Männistö & Tuominen 2000]. Of these 
acyclovir and its L-valyl ester valacyclovir are the most important. The other 
analogs are gancyclovir, pencyclovir, and famciclovir, the diacetyl ester of 6-
deoxy pencyclovir. Nucleoside analogs enter cells that have been infected by 
viruses and compete with deoxynucleosides for the viral thymidine kinase, 
which phosphorylates the analogs to monophosphates. These 
monophosphates are converted by cellular kinases to the diphosphate and 
triphosphate forms. For example, acyclovir triphosphate competes with 
deoxyguanosine triphosphate. The triphosphates act as substrates for viral 
DNA polymerase which incorporates them into the growing DNA strand 
where they interrupt chain elongation by terminating it.  
 
Acyclovir and valacyclovir have a limited effect against human herpesviruses 
[Erlich 1997; Männistö & Tuominen 2000]. However, HSV-1, HSV-2, VZV, 
and to some degree EBV are susceptible to it. Despite this narrow spectrum 
of activity, acyclovir has a very important role in prevention of disease and 
treatment of acute infections, e.g. common herpes in the facial area, genital 
herpes, varicella, herpes zoster, and encephalitis. Acyclovir can be 
administered locally but also orally or intravenously. One of its drawbacks is 
that herpesviruses develop resistance against acyclovir exceedingly fast and 
this phenomenom is a particularly serious problem to immunocompromised 
patients. The incidence of resistance has been estimated to be <10% in 
immunocompromised patients [Christophers et al. 1998]. Changes in 
thymidine kinase lead to incomplete phosphorylation of the drug. Mutations 
in viral DNA polymerase can also result in drug resistance.   
 
Gancyclovir and pencyclovir are also guanosine analogs [Männistö & 
Tuominen 2000]. Gancyclovir acts like acyclovir but it has activity againts 
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CMV and EBV. It is administrated intravenously and it also has severe side 
effects, such as neutropenia in over 35% of cases, and thrombocytopenia in 
~10% of treated patients. Due to gancyclovir`s side effects, it is only 
administrated in severe CMV infections.    
 
Pencyclovir`s phosphorylation to the monophosphate form depends on the 
thymidine kinase of HSV. HSV-1, HSV-2, and VZV DNA polymerases have a 
lower affinity for pencyclovir triphosphate than for acyclovir triphosphate, 
but pencyclovir invades the cell easier than acyclovir, thus, their relative 
activities are similar.  Famciclovir is a diacetyl ester of 6-deoxy pencyclovir, 
and it is known to be the orally active form of pencyclovir [Fangman, Rao & 
Myers 2003; Männistö & Tuominen 2000]. Famciclovir is rapidly and 
extensively absorbed and converted to pencyclovir during transit through the 
intestinal wall and liver. Famciclovir has been discovered to be more effective 
against zoster than acyclovir [Erlich 1997].     
 
A novel nucleotide analog called cidofovir contains a phosphonate group, 
and therefore does not require initial phosphorylation by a viral enzyme for 
activation like the other nucleoside analogs do. It has potent activity against, 
for example CMV [Fangman, Rao & Myers 2003].   
 
Foscarnet is a pyrophosphate analog which attaches to the pyrophosphate-
binding site of the virus-encoded DNA polymerase [Erlich 1997; Männistö & 
Tuominen 2000]. Binding to this site changes the conformation of the DNA 
polymerase. Foscarnet has activity against herpesviruses, but also against 
some retro-, and influenza viruses. Foscarnet is administered intravenously 
and it is used to treat herpes simplex and cytomegalovirus infections when 
acyclovir has lost its effectiveness.   
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3. DIAGNOSIS OF HUMAN HERPESVIRUS INFECTIONS 
 
The method used for diagnosis of the herpesvirus infections depends on the 
clinical manifestations of the patient. In diagnostics, herpesvirus antibodies, 
the virus or some part of the virus are detected. Serological assays for 
detection of virus-specific antibodies are used to detect an increase or 
decrease in antibody levels and seroconversion, or to explore the history of 
patient immunity status [Hukkanen et al. 2003; McKendrick et al. 2007]. In 
acute cases, antigens may be detected from, for example, vesicle samples. 
Some of the herpesviruses can be cultured from a sample and afterwards 
identified with various methods [Leland & Ginocchio 2007]. The nucleic 
acids of herpesviruses can be detected from various sample types by 
polymerase chain reaction (PCR) [Piiparinen and Vaheri. 1991; Vesanen et 
al. 1996; Koskiniemi et al. 1997; Chiu et al. 1998; Read & Kurtz 1999;  Espy 
et al. 2000; Pitkäranta et al. 2000; Read, Mitchell & Fink 2001; Aberle & 
Puchhammer-Stöckl 2002; Druce et al. 2002; Hudnall, Chen & Tyring 2004; 
Ihira et al. 2002;  Piiparinen et al. 2002; Aalto et al. 2003].  
 
In CNS infections, methods for diagnosis of herpesvirus infection include 
viral DNA detection with PCR and examination of intrathecally-produced 
antibodies [Koskiniemi et al. 2001; Aberle & Puchhammer-Stöckl 2002; 
Hukkanen et al. 2003; Schultze et al. 2004]. Generally, herpesvirus DNA and 
antibodies are not normally present in CSF, and therefore a positive DNA or 
IgM finding, or an increased ratio of IgG in CSF versus serum, can indicate 
CNS infection. However, the antibodies cannot be detected earlier than one 
week from onset of symptoms and therefore, during the first 7 to 10 days, 
methods detecting viral DNA are recommended in CNS infections [Hukkanen 
& Vuorinen 2002; Schultze et al. 2004; Kupila et al. 2006;]. In any case, 
serology is the method of choice in prolonged infections when nucleic acid 
detection may not provide sufficient information. 
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3.1. Serology  
 
Detection of specific immunoglobulins is of importance for determining 
immunological status with regards to herpesviruses. Immunity can be 
determined from serum sample and is important, for example, to women of 
child-bearing age, and to young children for determining the need for VZV 
vaccination [McKendrick et al. 2007]. Serological tests can also be used at, 
for instance, clinics for sexually-transmitted diseases, as confirmatory tests 
for genital herpes with atypical symptoms [Ashley-Morrow, Krantz & Wald 
2003]. The HSV-type specific serology has also significance in survey of 
genital herpes carriers and transmission.  
 
A significant rise in the IgG antibody level (4-fold increase) and 
seroconversion, or IgM seropositivity, can indicate an acute infection 
[Yoshikawa et al. 2000; Hukkanen et al. 2003]. In herpesvirus reactivation, 
elevated IgG levels and IgM antibodies can be observed. IgG-avidity assays 
can be used to distinguish between recent and past infections [Kneitz et al. 
2004].  
 
During primary infection of the skin or mucosa, specific antibodies to HSV-1 
and HSV-2 are often produced slowly and another serum sample should be 
tested 3-4 weeks after onset of symptoms with an enzyme-linked 
immunoassay (EIA). Therefore, the methods of choice for detection of acute 
infections of HSVs are virus culture and antigen detection. In acute 
chickenpox (varicella), shingles (herpes zoster), or obscure eczema with 
vesicles, EIAs for detection of antibodies to VZV are performed. If CMV 
infection is suspected during pregnancy, in transplantation or in 
immunosuppressed patients, or is thought to be suspected to be the 
causative agent of mononucleosis and fever, serological assays are 
performed. EIAs for EBV-antibody detection are used for instance when 
mononucleosis is suspected or sustained fever and lymphadenopathy are 
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observed. EBV antibodies can also be detected with an agglutination test of 
EBV IgM antibody, which is fast but not very accurate. It is, however, often 
sufficient for diagnosis [Hukkanen et al. 2003]. Primary HHV-6 or HHV-7 
infection can be determined with serological assays if e.g. exanthema 
subitum, pityriasis rosea, fever, or lymphadenopathy are observed.  
 
In serology, all the methods are based on interactions between antibody and 
antigen. Specific binding can be detected with various methods, some of 
which can also quantify the level of antigen-antibody binding. EIAs are often 
quantitative assays that can be used for examination of antibody levels 
[Schultze et al. 2004]. In EIA, the antigen can be coated onto wells and 
specific antibodies attached to antigens are detected with labeled anti-
human IgG or IgM. In -capture EIAs, the human IgMs are coated onto the 
wells and antibodies attached to IgM are detected with labeled herpesvirus 
antigens [Oladepo et al. 2000]. To differentiate acute from past infections, 
avidity assays have been developed for herpesviruses [Hukkanen et al. 2003; 
Kneitz et al. 2004]. Avidity assays are based on the separation of low- and 
high-avidity antibodies, indicating acute and past infection, respectively. The 
separation is done using a denaturant such as urea.  
 
EIAs based on recombinant antigen or virus lysate have been developed and 
are commercially available for several herpesviruses [Weinberg et al. 1996; 
Weber, Berger & Rabenau 2001; Ashley 2002; Wald & Ashley-Morrow 2002; 
Sauerbrei & Wützler 2006]. In EIAs that differentiate HSV-1 and HSV-2, 
glycoprotein G is often used as an antigen [Ashley 2002; Wald & Ashley-
Morrow 2002]. However, HSV-2 strains comprising silent gG gene have been 
found which suggests that some mutated strain may not be detected with 
serological assays [Nordberg et al. 2007]. The envelope glycoproteins of VZV 
are highly immunogenic and glycoproteins such as VZV glycoprotein G have 
also been used in VZV-specific EIAs [Sauerbrei & Wützler 2006]. Recently, a 
new multiplex fluorescent microsphere immunoassay for the determination 
of EBV serologic status was evaluated [Martins, Litwin & Hill 2008].  
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Complement fixation (CF) tests can be used to reveal viral etiology in the 
case of unclear fever or rash of unknown origin. Of the herpesviruses, HSV, 
VZV, and CMV CF assays can be used in diagnostics [McHugh et al. 1985; 
Hukkanen et al. 2003]. In the CF test, herpesvirus antigen and complement 
are added to a diluted serum sample. An indirect immunofluorescence assay 
(IFA) can be used to determine antibody titers against herpesviruses [Landry 
et al. 1987; Yoshikawa et al. 2001]. The herpesvirus-infected cells are grown 
on glass microscope slides and diluted serum or CSF is added, so that the 
herpesvirus antibodies attach to the cells. The binding is detected with 
fluorescein-labeled anti-human IgG or IgM.  However, this assay is unable to 
distinguish herpesviruses with cross-reacting antibodies, e.g. HHV-6 and 
HHV-7. 
  
Other serological assays are immunoblotting, which specifically detects both 
IgG and IgM, and the neutralization test, which is generally considered to be 
a type-specific serological assay for most virus infections [LaCroix et al. 
2000; Yoshikawa et al. 2001]. Radioimmunoassays and latex agglutination 
have also been used for screening of herpesvirus antibodies [Slomka et al. 
1995; Svahn et al. 1997].  
 
3.2. Viral culture 
 
Virus isolation by culturing is used in HSV and VZV infections of the skin 
and mucosa. Cells from the eye or mucosa (vesicles) of the throat, cervix or 
urethra, can be sampled and inoculated into cell lines of choice to cultivate 
viruses. However, HSV-1, HSV-2, and VZV are not very commonly isolated 
from CSF [Hukkanen & Vuorinen 2002; Kupila et al. 2006]. CMV infection 
can be identified by culturing urine or throat swab samples. Virus isolation 
can be used for identification of perinatal or neonatal infection, and a 
positive finding indicates active virus infection [Kimberlin 2004].         
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Appropriate collection, transport and processing of clinical samples are 
important for virus isolation in cell cultures. After an appropriate time, the 
inoculated cell cultures are examined with microscopy for any cytopathic 
effect (CPE) appearing in cell monolayer, or virus is identified by detection of 
virus-specific antigens. The CPE is caused by viral replication and may be 
seen as swelling, rounding, shrinking, or clustering of the cells, syncytium 
formation or even as total destruction of the monolayer. HSVs may produce 
a visible CPE within 24 h of inoculation, but with CMV, it can take an 
average of 10–30 days, and therefore other, faster, culturing methods have 
been developed [Leland & Ginocchio 2007]. CPE formation by VZV is seen in 
6-8 days.  
 
The shell vial system was developed for rapid CMV isolation. At the time of 
inoculation, the vial is low-speed centrifuged, and after a brief incubation 
(~16-24 h) the cells are stained with a monoclonal antibody to early proteins 
of CMV [Gleaves et al. 1984]. Since it has proven successful, this shell vial 
system has been adapted to, for instance, HSV and VZV isolation. Rapid 
assays for CMV and HSV based on shell vial system have been used in 
diagnostics [Ziegler et al. 1988; Diamond et al. 2000]. The next advance in 
the diagnostic methods involved using different cell types, which were 
combined to grow together as a monolayer [Leland & Ginocchio 2007]. In 
this way, different viruses with different target cells could be cultivated 
simultaneously from the same sample. Currently, several commercially 
produced co-cultivated cell lines are available (Diagnostic Hybrids Inc., 
Athens, OH) and shell vial systems are also available commercially. In 
addition, EBV and HHV-6 can be cultivated in lymphocytic cell lines but they 
are cumbersome to culture, and therefore other methods are used for their 
detection [Hukkanen et al. 2003].  
 
 
REVIEW OF THE LITERATURE 
 Microarrays in Human Herpesvirus Diagnostics - 28 
3.3. Antigen detection 
 
Direct detection of herpesvirus antigens can be used in acute cases, e.g. 
primary infections with vesicle formation. For example, HSV and VZV 
antigen detection can be used for diagnosis of acute infection during 
childbirth or in newborns or immunosuppressed patients [Hukkanen et al. 
2003]. HSV and VZV antigens can be detected from samples with an 
adequate number of cells containing virus antigens. The sample can be 
taken from the bottom of a broken blister, lesion or mucosa. The virus-
specific antigens are detected by immunofluorescence microscopy and 
labeled virus-specific antibodies. Positive findings are an indication of 
primary infection, possible reactivation or reinfection. Occassionally, HSV 
carriers secrete the virus without any symptoms. In the acute phase, there 
can be only a few antigen-presenting cells. To increase sensitivity, it is 
recommended that virus is cultivated prior to viral antigen detection. The 
determination of phosphoprotein 65 (pp65) antigenemia has long been the 
reference test for monitoring CMV reactivation in transplant or 
immunosuppressed patients [Piiparinen et al. 2004; Cariani et al. 2007]. 
Monoclonal antibodies to pp65 are used for immunostaining of blood 
polymorphonuclear leukocytes. Real-time PCR methods for detection and 
quantification of CMV DNA have been suggested as a convenient alternative 
to the antigenemia test.  
 
3.4. Polymerase chain reaction methods – qualitative and 
quantitative  
 
Diagnostic tools have been developed for reliable and fast identification of 
herpesviruses. Polymerase chain reaction (PCR) and its numerous 
applications have been successfully used for laboratory diagnosis of e.g. CNS 
infections or monitoring of CMV and EBV DNA quantity in plasma. PCR can 
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be qualitative or quantitative and is used for detection of viral nucleic acid or 
quantification of the viral load in a sample.  
 
Conventional PCR is based on amplification of a specific DNA sequence. 
Many PCR procedures have been developed, and a considerable number of 
them are used in diagnostics of human pathogens. The principles of PCR are 
thoroughly described elsewhere [Guatelli, Gingeras & Richman 1989]. In 
short, the genomic area of interest is amplified with PCR. First, the target 
genomic DNA is denatured. The specific primer pair (short ssDNA 
oligonucleotides) finds and anneals its complementary sequence in the 
genome. DNA polymerase uses the primer as a starting point and 
synthesizes the complementary strand by adding deoxyribonucleotides. The 
cycles of denaturating, annealing of primers to genomic DNA and extension 
are repeated and after final extension the product can be detected by 
visualization. The denaturation, annealing and extension are accomplished 
by changing the temperatures in amplification program.    
 
Sensitive PCR-based methods have been developed for detection of human 
herpesviruses, and they are widely used in diagnostics [Echevarria et al. 
1994; Vesanen et al. 1996; Koskiniemi et al. 1997; Pitkäranta et al. 2000; 
Koskiniemi et al. 2002; Hukkanen et al. 2003a; Kupila et al. 2006; Hanson 
et al. 2007; Mannonen et al. 2007]. Multiplex-PCR methods for simultaneous 
detection of numerous herpesviruses have also been developed. In these 
applications, either one generic primer pair for the targets or several 
separate target-specific primer pairs are used. Multiplex-PCR is able to 
amplify several targets simultaneously in one reaction and therefore, it can 
be used in place of several sequential PCR reactions. One of the earliest 
multiplex-PCR methods for detection of herpesviruses was described in 1996 
[Jackson et al. 1996]. Since then, multiplex-PCR methods or a multiplex 
nested-PCR method, in which two rounds of PCR reactions are performed, 
have been developed for simultaneous identification of several herpesviruses 
[Pozo & Tenorio 1999; Read & Kurtz 1999; Markoulatos et al. 2000; 
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Markoulatos et al. 2001; Calvario et al. 2002; Druce et al. 2002; Hudnall, 
Chen & Tyring 2004; Tafreshi et al. 2005]. They were specific, but the 
sensitivities of multiplex-PCR methods varied depending on detected 
herpesviruses. Today, the multiplex-PCR methods are developed aiming at 
faster, simpler and more cost-effective diagnostics [Bergallo et al. 2007].  
 
PCR-based methods, in which amplification is monitored and visualized on-
line, are called real-time PCRs. Qualitative real-time PCRs have been 
developed for identification of herpesvirus DNAs [Espy et al. 2000; Tang et 
al. 2007]. In addition, commercial real-time PCRs are already available, for 
instance for typing of HSVs [Podzorski 2006]. A few multiplex real-time PCR 
methods for HSV-1, HSV-2, and VZV have also been developed [O'Neill et al. 
2003; Read, Mitchell & Fink 2001]. The sensitivities of multiplex real-time 
PCRs have been found to be similar to those of single or multiplex-PCRs. 
Possibly due to the difficulty of setting up a highly sensitive and specific 
multiplex real-time PCR for simultaneous identification of several 
herpesviruses in one reaction, separate real-time PCRs for single virus 
detection have been developed [Stöcher et al. 2003]. These PCRs for HSV-1, 
HSV-2, VZV, CMV and EBV DNA detection can be simultaneously amplified 
using the same parameters in separate reactions with virus-specific primer 
pairs.  
 
Quantitative PCR-based methods are performed if CMV or EBV infections are 
suspected in an immunosuppressed patient [Aalto et al. 2003; Piiparinen et 
al. 2005]. For example, the amount of EBV DNA reflects the severity of EBV 
infection, and therefore viral DNA levels in clinical sample are followed 
during antiviral therapy. In addition to quantification of CMV and EBV DNA 
in clinical sample, quantitative real-time PCRs have also been published for 
diagnostics of HSVs, VZV, HHV-6, and HHV-7 [Kimura et al. 1999; Nitsche 
et al. 1999; Pevenstein et al. 1999; Ryncarz et al. 1999; Zerr et al. 2000]. 
Recently, a quantitative multiplex real-time PCR for EBV, CMV and HHV-6 
was developed and tested with samples from transplant recipients [Wada et 
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al. 2007]. The results indicated that developed multiplex assay was as 
sensitive and specific as those of a single real-time PCR.  
 
In 1991, a time-resolved fluorescence-based hybridization assay combined 
with PCR was described [Dahlen et al. 1991]. For herpesvirus detection, a 
time-resolved fluorometry (TRF) PCR assay was developed in 2000, which 
was further modified for simultaneous detection of HSV, VZV, CMV and 
enteroviruses in CNS infections [Hukkanen et al. 2000; Hukkanen & 
Vuorinen 2002]. A fully automated, homogeneous nucleic acid detection 
technique based on dry-reagent assay chemistry and time-resolved 
fluorometry was recently described, indicating the potential of this approach 
for nucleic acid detection and diagnosis [von Lode et al. 2007]. In the PCR-
ELISA technique, labeled amplicons are hybridized to specific probes and 
colorimetric reaction is performed in microtiter wells [Musiani et al. 2007]. 
This technique has been applied for identification of human 
papillomaviruses and herpesviruses [Vesanen et al. 1996; Musiani et al. 
2007]. 
 
4. MICROARRAY METHODS  
 
Microarrays have been used in various fields of biosciences, such as studies 
of single nucleotide polymorphisms, gene expression and microbiology 
[Borsting, Sanchez & Morling 2004; Chambers et al. 1999; Huber et al. 
2002; Pastinen et al. 2000; Sachse et al. 2005]. Microarrays consist of 
biomolecules attached to the solid support, which is typically glass, silicon, 
nylon membrane, or plastic [Cretich et al. 2006; Pastinen et al. 2000; Sachse 
et al. 2005]. The immobilized biomolecules can be oligonucleotides, PCR 
products, proteins, peptides, carbohydrates, or other small molecules. These 
biomolecules are arranged in predetermined order on a solid support, e.g. 
slides. In one array, there can be dozens or thousands of biomolecules. In 
microarray, there can be many separate arrays each targeted to different 
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sample, or just one large array on which only one sample is hybridized. The 
samples tested can be cellular extracts, PCR products, or antibodies, all of 
which can hybridize or attach to the biomolecules on the microarray.  
 
Today, commercial nucleic acid microarrays are available for a number of 
applications such as gene expression studies and identification of nucleic 
acids from viral pathogens. Antibody microarrays are also commercially 
available for research purposes to study cellular processes such as 
apoptosis.  
 
4.1. Nucleic acid microarrays for identification of viruses 
 
The first viral microarrays were described a few years ago [Chizhikov et al. 
2002; Wang et al. 2002; Wilson et al. 2002; Sengupta et al. 2003]. At the 
moment, there are numerous microarray methods which are used in viral 
studies. Some of these methods, especially the ones for herpesvirus 
detection, are presented in more detail in next chapter (Fig. 1). In short, all 
of these methods are based on the PCR assay and visualization of the PCR-
product with different methods on the microarray [Wang et al. 2002; Wang et 
al. 2003; Lovmar et al. 2003; Boriskin et al. 2004; Klaassen et al. 2004; 
Korimbocus et al. 2004; Striebel et al. 2004; Albrecht et al. 2006; Lopez-
Campos et al. 2007; Baek et al. 2008]. Microarray technology provides a 
promising approach for clinical microbiology, and a number of methods for 
detection and genotyping of adeno-, influenza-, corona-, zoonotic, rota-, 
noro-, astro-, entero-, papilloma- and respiratory tract viruses have already 
been introduced [Chizhikov et al. 2002; Wilson et al. 2002; Sengupta et al. 
2003; Gemignani et al. 2004; Coiras et al. 2005; Nordström et al. 2005; 
Chou et al. 2006; Gheit et al. 2006; Jääskeläinen & Maunula 2006; Min et 
al. 2006; Ryabinin et al. 2006; Hsia et al. 2007; Liu et al. 2007].  
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 Fig. 1. Examples of microarray-based techniques for identification of viral nucleic acids. 
 
All microarray methods for viral nucleic acid detection are based on PCR 
combined with microarrays with either oligonucleotides or longer DNA-
fragments bound to the arrays. A common approach is to hybridize PCR 
product to oligonucleotides, and specific hybridization is visualized with a 
fluorescence or colorimetric reaction, i.e. enzyme catalyzed substrate 
precipitation. Microarrays provide a method to detect multiple PCR products 
in an efficient and sensitive manner. A small amount of amplicon is needed 
for detection, and scanners and readers for microarrays are capable of 
visualization even minimal fluorescence or color reactions. For example, 
ScanArray Express –laser scanner (PerkinElmer, Wellesley, MA), which is 
used for microarray reading, can reach the sensitivity of <0.1 fluorescent 
molecule per m2. With microarrays, numerous of viral targets may be 
identified simultaneously from various samples. These features make the 
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microarray a very efficient and multifunctional tool for screening purposes 
and diagnosis.  
 
Microarray assay for detecting 140 viruses, e.g. human rhino-, respiratory 
syncytial, parainfluenza, and adenoviruses, were described in 2002 [Wang et 
al. 2002]. The microarray consisted of 70-mer oligonucleotides. The RNA 
from samples was extracted and reverse-transcribed with a primer 
consisting of specific sequence followed by random sequence (Fig. 1). The 
PCR reaction was carried out using primers for the specific part of the first 
primer. The PCR-product was labeled afterwards in a separate reaction with 
random primers, enzyme and aminoallyl-labeled nucleotides, which were 
used to capture cyanine dye. After hybridization, fluorescence was detected. 
Wang et al. [2003] also published another microarray study, based on above 
presented publication. In this study, they increased the microarray from 140 
viruses to a pan-viral microarray for ~1000 viruses with a total of 100 000 
70-mer oligonucleotides on the microarray. This microarray was used as 
part of the global effort to identify the virus associated with severe acute 
respiratory syndrome (SARS). With this microarray, they captured the novel 
virus, which was futher isolated from microarray spots and PCR amplified. 
This fragment was further cloned and sequenced to confirm that the 
captured virus was a new coronavirus.   
   
A microarray method for identification of human rotaviruses was introduced 
by Lovmar et al. [2003], and this method was based on human rotavirus-
specific oligonucleotides which were covalently immobilized on glass 
microscope slides (Fig. 1). Oligonucleotides were used to capture RT-PCR 
products, and the bound template was then was extended using fluorescent 
nucleotides and a thermostable DNA polymerase. Finally, the fluorescence 
intensity was measured using a microarray scanner.  
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A microarray method which was based on digoxigenin-labeled human 
papillomavirus-derived PCR amplicons was described by Klaassen et al. 
[2004]. The PCR-amplicons were hybridized onto type-specific biotinylated 
probes immobilized on streptavidin-coated glass slides. These hybridized 
amplicons containing digoxigenin were treated with a mouse monoclonal 
antibody specific for digoxigenin (Fig. 1). Alkaline phosphatase-conjugated 
rabbit anti-mouse immunoglobulins attached to the mouse monoclonal 
antibody, and alkaline phosphatase activity was detected using a substrate, 
i.e. colorimetric reaction. This microarray was designed for detection and 
subtyping of human papillomaviruses.  
 
Boriskin et al. [2004] developed a microarray method in which they amplified 
herpesvirus, enterovirus and flavivirus nucleic acids with multiplex-PCR and 
RT-PCR. The PCR products were further labeled in a separate reaction with 
random primers, cyanine-labeled nucleotides and enzyme, followed by 
denaturation, overnight hybridization on the microarray and finally detection 
(Fig. 1). They used the same gel-purified PCR products as the probe elements 
on the microarray after generating them from the viral DNA or RNA template. 
Other studies using similar principles in PCR and microarray methods have 
been carried out. Striebel et al. [2004] described a microarray method for 
herpesvirus detection which was based on PCR with cyanine-labeled 
primers. These primers were branched at the 5´end, and each branch 
contained cyanine label (Fig. 1). In addition, Albrecht et al. [2006] used 
cyanine-labeled PCR-primers as a second primer set in the nested-PCR for 
human papillomaviruses, in which two sequential PCR reactions are 
performed using the PCR-product from first PCR as a template to second one 
(Fig. 1). They spotted sense and antisense oligonucleotides with spacer 
sequence on microarray. The denaturated PCR product was hybridized to the 
oligonucleotides on the microarray and signal was detected. Lopez-Campos 
et al. [2007] designed a microarray for human adenoviruses that was based 
on oligonucleotides on microarrays and nested-PCR. The labeling was 
performed using cyanine-labeled nucleotides in the second round of nested-
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PCR followed by denaturation, hybridization on microarrays and detection 
(Fig. 1).  
 
Korimbocus et al. [2005] introduced a microarray method for detection of 
herpes-, flavi- and enteroviruses in CNS infections. This method was based 
on three separate and generic PCR reaction products which were pooled 
labeled with meta-biotinphenylmethyldiazomethyl, followed by fragmentation 
with hydrochloric acid before hybridization to a microarray (Fig. 2). The 
hybridized fragments were stained using streptavidin labeled with R-
phycoerythrin, which is a phycobiliprotein purified from red macroalgae and 
is used as a fluorochrome for fluorescent assays.   
 
 
Fig. 2. Examples of microarray-based methods for detection of viral nucleic acids 
where biotin-labeled PCR products are hybridized on oligonucleotides attached 
to solid support.    
 
Recently, a microarray system using a bipolar integrated circuit photodiode 
array was described by Baek et al. [2008] for human papillomavirus 
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detection. The amino-linked oligonucleotides were immobilized to the 
microarray and PCR with biotin-labeled PCR-primers was carried out. The 
denaturated PCR-products were hybridized to the oligonucleotide 
microarray, followed by reaction with an anti-biotin antibody-conjugated 
gold nanoparticle solution (Fig. 2). The silver enhancement reaction was 
performed before finally washing, drying and reading the microarray. 
 
4.2. Serological microarrays 
 
In serological microarrays, antigens are immobilized to solid supports for 
capturing the antibodies of choice. These analytical microarrays can be used 
to detect antibodies from serum samples for determination of immunity 
status, infection, allergy diagnostics or autoimmune diseases [Blixt et al. 
2007; Bonhomme, Nappez & Raoult 2007; Cretich et al. 2006; Davies et al. 
2008; Lin et al. 2007; Mezzasoma et al. 2002; Spisak et al. 2007]. 
Immunogenic proteins spotted on the microarrays can be used to detect 
disease with diagnostic potential. Antigens such as recombinant proteins or 
bacterial suspensions can also be immobilized on the microarray. The 
primary antibodies recognize specific antigens on the microarray and 
secondary antibodies with coupled fluorescent labels or other detection 
molecules are used to visualize the bound antibody.  
 
Only a few serological microarrays for viral antibody detection have been 
developed. A microarray has been described for detection of antibodies 
directed against Toxoplasma gondii, rubella virus, CMV and HSV-1 and -2 
(ToRCH antigens) [Mezzasoma et al. 2002]. Parallel detection of nucleic acids 
and antibodies to human immunodeficiency, hepatitis B and hepatitis C 
viruses with microarrays has also been described by Perrin et al. [2003]. 
Detection was based on nucleic acid probes, viral proteins and nonspecific 
proteins on a microarray (Fig. 3). The enzyme-labeled secondary antibody 
was used for detection of antibody that was captured by antigen on a 
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microarray, and the enzyme-labeled streptavidin was used for detection of 
captured biotinylated PCR products. The insoluble substrate was used to 
obtain colorimetric reaction catalyzed by enzyme.    
 
Fig. 3. Microarray in which viral antigen and oligonucleotides are spotted on a 
solid support and detected using alkaline phosphatase –labeled secondary 
antibody or streptavidin attached to biotin labeled PCR product. 
 
Microarrays have been designed for detection of SARS coronavirus 
antibodies using structural proteins as antigens [Lu et al. 2005]. Viral 
antibodies bound to the antigens on the microarray were detected by a 
cyanine-labeled secondary antibody. Sera from SARS patients were also 
tested using this microarray.  Another coronavirus microarray was described 
in which entire or partial proteomes of the human SARS coronavirus and 
other human (HCoV-229E, HCoV-OC43), mouse, bovine, and feline 
coronaviruses were used as antigens [Zhu et al. 2006]. Human-anti-SARS 
antibodies were detected by cyanine-labeled goat anti-human IgGs acting as 
secondary antibodies.  
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An integrated protein microarray was developed for simultaneous detection 
of two viral antigens of hepatitis virus B and seven viral antibodies of human 
hepatitis B, C, D, E, and G viruses in human sera [Xu et al. 2007]. Another 
microarray was developed for hepatitis C antibody detection to be used for 
screening of, for example, blood banks [Kwon et al. 2008]. Four different 
antigens for hepatitis C virus were spotted into the wells of 96-well plates 
coated with sol-gel, and secondary labeled antibodies were used for 
detection. The captured hepatitis C antibody was detected by cyanine-
labeled secondary antibody. 
 
Recently, microarray techniques were also used for immunogenicity studies 
of a modified vaccinia virus Ankara. This virus was a highly attenuated 
vaccinia virus that is under consideration as an alternative to the 
conventional smallpox vaccine Dryvax. The antibody response for both 
modified vaccinia virus Ankara and the smallpox vaccine Dryvax was studied 
by comparing microarray profiles [Davies et al. 2008].   
 
Protein microarray technology can be considered challenging due to the 
complex nature of proteins. The purity of the protein and maintenance of its 
native state when immobilized onto the surface of a microarray (including 
spotting and storage conditions) have an outcome on the effectiveness of the 
microarray. Recently, a new method which could overcome the problems of 
long-term storage or spotting of the replicate protein microarrays has been 
introduced by He et al. [2008]. In this method, PCR-amplified fragments 
encoding a set of tagged proteins are spotted on the solid support. When 
protein microarrays are needed, a permeable membrane carrying a cell-free 
lysate, capable of performing transcription and translation, is placed 
between cDNA microarray and the second slide, which is coated with tag-
capturing reagent. The synthesized proteins diffuse through the membrane 
and become rapidly immobilized on the capture slide surface comprising a 
protein microarray corresponding to the cDNA microarray.   
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AIMS OF THE STUDY  
  
The aims of the present study were: 
  
 To develop a multiplex-PCR and microarray method for 
simultaneous detection of HSV-1, HSV-2, VZV, CMV, EBV, HHV-
6A, HHV-6B, and HHV-7 from clinical specimens (, ) 
 
 To further evaluate and improve the microarray method for 
detection of HSV-1, HSV-2, and VZV from cerebrospinal fluid () 
 
 To develop an antigen-based serological microarray for detection of 
HSV-1, HSV-2, VZV and CMV antibodies and to evaluate the 
effectiveness of the serological microarray as a fast screening tool 
(V) 
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MATERIALS AND METHODS 
  
1. MULTIPLEX-PCR AND MICROARRAY METHOD (, , ) 
 
1.1. Clinical specimens 
 
The clinical samples were from the Department of Virology, Helsinki 
University Hospital, Laboratory Services (HUSLAB). The clinical specimens 
consisted of whole-blood, cerebrospinal fluid (CSF), plasma and proficiency 
testing samples (described below). Ten whole-blood, 23 CSF, and 73 plasma 
samples were collected from solid organ and bone marrow transplant 
patients, and patients with neurological symptoms. Altogether, 10 samples 
from the VZV (4) and HSV (6) proficiency-testing program 2004 (QCMD, 
Glasgow, Scotland, UK) were included and all the specimens were screened 
in parallel with routine PCR methods and a multiplex-PCR and microarray 
method (). The negative panel, consisting of 70 sera, 30 CSF and 11 
proficiency testing samples from an enterovirus 2004 program, were also 
tested with the microarray method (). Cell culture supernatants of HHV-6A 
strain GS and an in-house strain, and HHV-6B strain Z-29 () were tested 
with the microarray. Twenty CSFs positive and two negative for HSV-1, HSV-
2 and VZV were collected and tested with the improved microarray (). 
 
Seventy CSFs, collected from the Department of Otorhinolaryngology, 
Helsinki University Hospital from 1998 to 2002, were tested with microarray 
method () in order to screen herpesviruses from FP patients and a control 
group. There were 33 peripheral FP patients (34 samples): 26 with Bell’s 
palsy (27 samples), five cases with simultaneous herpesvirus infections, one 
with puerperal FP (two weeks after delivery), and one with Melkersson-
Rosenthal syndrome. 
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1.2. Viral DNA controls 
 
Quantitated commercial viral DNA controls (, ) were used to determine the 
sensitivity and specificity of the assay. The copy numbers refer to genome 
copy number, which has been determined by the manufacturer with 
quantitative PCR. Viral particles (VPs) refer to the viral particle count based 
on the amount of active virus prior to nucleic acid extraction, as determined 
by the manufacturer (Advanced Biotechnologies, Columbia, MD).  
  
1.3. Multiplex-PCRs  
 
1.3.1. DNA extraction 
 
DNA was extracted from 200 l of CSF () and 500 l of whole blood () with 
phenol-chloroform. The precipitate from CSF was resuspended in 22 l and 
that from whole blood in 100 l of sterile water. DNA from 200 l of CSF 
from a negative panel or sera/plasma () was extracted using the MagNA 
Pure LC instrument and a Total Nucleic Acid Kit (Roche Diagnostics, Basel, 
Switzerland), and DNA from 200 l of CSF (, ) was extracted using a High 
Pure Viral Nucleic Acid Kit (Roche Diagnostics) according to the 
manufacturer’s instructions and with elution by 50 l of elution buffer.  
 
1.3.2. Original and improved multiplex-PCRs 
 
The original multiplex-PCR-1 was used to identify HSV-1 and HSV-2 
resulting in a 264-bp amplicon (, primers in Table 1). Multiplex-PCR-2 
contained primer pairs for amplification of CMV, EBV, VZV, HHV-6A, HHV-
6B and HHV-7, resulting in 220 bp, 273 bp, 186 bp, 179 bp (both HHV-6A 
and HHV-6B) and 230 bp PCR-products (Table 1), respectively. The improved 
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multiplex-PCR-1 () contained a new primer pair for HSV amplification (a 
249-bp amplicon, primers given in Table 1).  
 
TABLE 1. Primers used in original and improved multiplex-PCRs (, ). 
FW, forward primer (sense); RV, reverse primer [anti-sense, T3 RNA polymerase promoter sequence (PSeq) 
PSeq- = AATTAACCCTCACTAAAGGGAGA comes before the virus sequence]; OP, Original publication 
where PCR primer was used; MPLEX ID indicates what primers are in the same PCR reaction [M1: 
HSV primers (), M2: HSV primers (), M3: other than HSV primers (both  and )].    
* Underlined AA nucleotides are match for HSV-2 and not included to HSV-1 position numbers. 
 
The original () and improved () multiplex-PCR-1 methods were used to 
identify HSV-1 and HSV-2, and they were carried out in a final volume of 50 
l containing 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 0.01% (w/vol) gelatin, 
0.2 mM dNTPmix (Finnzymes, Espoo, Finland), 0.6 M of primers, 12.5 U 
AmpliTaq Gold polymerase (Applied Biosystems, Foster City, CA) and 2 mM 
MgCl2. The multiplex-PCR-2 was performed in a final volume of 53 l 
containing 47.2 mM KCl, 9.4 mM Tris-HCl (pH 8.3), 0.009% (w/vol) gelatin, 
0.19 mM dNTPmix (Finnzymes), 0.56 M of each primer, 12.5 U AmpliTaq 
Primer 
(OP) 
Sequences (5’→ 3’), MPLEX ID. Gene  Genus (GenBank Acc. No), 
Position 
HSV-FW  
() 
AAGGAGGCGCCCAAGCGCCCG, M1 DNA pol. * HSV-1 (X14112), 64750 – 64768; 
HSV-2 (Z86099), 65209 – 65229 
HSV-RV  
() 
PSeq-TGGGGTACAGGCTGGCAAAGT, M1 
 
HSV-1 (X14112), 64976 – 64956;  
HSV-2 (Z86099), 65449 – 65429 
HSV-FW  
() 
AGCGAATTCGAGATGCTG(T/C)T, M2 
 
HSV-1 (X14112), 64130-64150; 
HSV-2 (Z86099), 64591-64611 
HSV-RV  
() 
PSeq-CCTT(T/G)ATCTTGCTGCGCTTC, M2 
 
HSV-1 (X14112), 64335-64355;   
HSV-2 (Z86099), 64796-64816 
VZV-FW  
(, ) 
CCATTTTCTCGCCGATTTTA, M3 DNA pol., 
ORF28 
VZV (AY548171), 48508 – 48527 
 
VZV-RV  
(, ) 
PSeq-GCCGCATTTGAACGTTTTAT, M3 VZV (AY548171), 48670 – 48651 
CMV-FW  
(, ) 
GTACAACAGCGTGTCGTGCT, M3 Processivity 
subunit of 
DNA pol, 
UL44 
CMV (AY446894), 57044 – 57063 
CMV-RV  
(, ) 
PSeq-CACCGGCCATCAAGTTTATC, M3 CMV (AY446894), 57240 – 57221 
EBV-FW  
(, ) 
CGTAGATGACTCGAAGCTG, M3 DNA pol., 
BALF5 
EBV (AJ507799), 154029 – 154047 
 
EBV-RV  
(, ) 
PSeq-ACCATCCTCGACAAGCAG, M3 EBV (AJ507799), 154278 – 154261 
HHV-6-FW  
(, ) 
CTCGATCGAATCCGTAAACA, M3 DNA pol., 
U38 
HHV-6A  (X83413), 59289 – 59308; 
HHV-6B  (AF157706), 60409 – 60428 
HHV-6-RV  
(, ) 
PSeq-CCGCGTATGTTTTATCGAGAC, M3 HHV-6A  (X83413), 59444 – 59424; 
HHV-6B  (AF157706), 60564 – 60544 
HHV-7-FW  
(, ) 
AGGTCCAACATGCACAGTGA, M3 DNA pol., 
U38 
HHV-7 (AF037218), 56787 – 56806 
HHV-7-RV  
(, ) 
PSeq-GGCAAAGAAAATGTGGGCTA, M3 HHV-7 (AF037218), 56993 – 56974 
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Gold polymerase (Applied Biosystems) and 1.9 mM MgCl2. The amplification 
consisted of denaturation at 95C for 10 min, followed by 40 cycles of 96C 
for 10 s, 55C for 20 s and 72C for 20 s and final extension at 72C for 5 
min. Five and 10 l of template were used for multiplex-PCR-1s of HSVs, and 
multiplex-PCR-2 of VZV, CMV, EBV, HHV-6A, HHV-6B, and HHV-7, 
respectively. 
 
1.4. PCRs for daily diagnostics (, ) 
 
Three qualitative PCRs for HSVs, HHV-6, and VZV, and two real-time 
quantitative PCRs (qPCRs) for CMV and EBV, were used in HUSLAB 
diagnostics in 2005. The HSV-PCRs were performed according to Piiparinen 
& Vaheri [1991] using the probes reported by Vesanen et al. [1996]. The 
primers designed by Gopal et al. [1990] were used to carry out PCR for HHV-
6, and the HHV-6 probe reported in Pitkäranta et al. [2000] was used to 
detect the HHV-6 amplicon. VZV-PCR was done according to Echevarria et 
al. [1994] and Koskiniemi et al. [1997]. Microplate hybridization with 
luminometric detection [Vesanen et al. 1996] was used for the detection of 
qualitative PCR products. qPCR for CMV was performed according to 
Piiparinen et al [2004]. EBV primers and a probe designed by Kimura et al. 
[1999] were used for the EBV qPCR based on a modification from Aalto et al. 
[2003]. 
 
1.5. Microarray design 
 
Microscope glass slides activated as described by Guo et al. [1994], modified 
according to Pastinen et al. [2000] (, ), or SAL-1-slides (Asper Biotech, 
Tartu, Estonia) () were spotted using a microarrayer (OmniGrid, 
GeneMachines, Huntingdon, UK). Oligonucleotides were spotted in 20 M 
concentration in 0.3 M sodium carbonate buffer (pH 9.0) () or 1MSS 
(ArrayIt, TeleChem International, Inc., Sunnyvale, CA) (, ) on microscope 
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slides. The oligonucleotides are described in Table 2. The spotting was 
performed at room temperature and at 50% humidity. The slides were stored 
overnight at room temperature before use.  
 
TABLE 2. Oligonucleotides used for herpesvirus identification on microarray (, ).  
Oligos (OP) Sequences (5’→ 3’), Microarray ID. Genus (GeneBank Acc. no), 
Position 
HSV-1-T3 () Am-TTTTTTTTTGTCCTTGACCCCACTT, M1 HSV-1 (X14112), 64907 – 64922 
HSV-2-T3 () Am-TTTTTTTTTAGGATAAGGACGACGAC, M1 HSV-2 (Z86099), 65279 - 65295 
HSVG1-T3* () Am-TTTTTTTTTGGTACAACATCATCAACTTC, 
M2 
HSV-1 (X14112), 64197 - 64218;  
HSV-2 (Z86099), 64658-64678 
HSVG2-T3* () **Am-TTTTTTTTTGGGACATAGGCCAGAG, M2 HSV-1 (X14112), 64311 - 64326;  
HSV-2 (Z86099), 64772 - 64787 
HSV-1-T3 () Am-TTTTTTTTTCAAGCTGACGGACATT, M2 HSV-1 (X14112), 64238 - 64254 
HSV-2-T3 () Am-TTTTTTTTTCAAGCTGACGGAGATC, M2 HSV-2 (Z86099), 64699 - 64715 
VZV-T3 (, ) Am-TTTTTTTTTACCTCGTACGCTTTTTG, M1  VZV (AY548171), 48597 - 48613 
VZV_1-T3 () Am-TTTTTTTTTAGAATCCGTATCTCCATATA,  
M1, M2 
VZV (AY548171), 48569 - 48588 
VZV_2-T3 () Am-TTTTTTTTTCAGAATCCGTATCTCCATAT,  
M1, M2 
VZV (AY548171), 48568 - 48587 
CMV-T3 (, ) Am-TTTTTTTTTGTAGAAGTTCTTCAGCTGC,  
M1, M2 
CMV (AY446894), 57122 - 57140 
GCMV-T3 () Am-TTTTTTTTTGTTGATACGCATGTTTTT, M2 CMV (AY446894), 57143 - 57160 
EBV-T3 (, ) Am-TTTTTTTTTGAGAGGCAGGGAAAGAGG,  
M1, M2 
EBV (AJ507799), 154184 - 154201 
GEBV-T3 () Am-TTTTTTTTTGCACGTGCACTTGAT, M2 EBV (AJ507799), 154237 - 154251 
GHHV-6-T3* () Am-TTTTTTTTTCAGTAAATACTGTCGGTCTC, 
M2 
HHV-6A (X83413), 59409 - 59428;  
HHV-6B (AF157706), 60529 – 60548  
HHV-6A-T3  
(, ) 
Am-TTTTTTTTTATCCTTGGACCGAGCTA,  
M1, M2 
HHV-6A (X83413) 59361 - 59377  
HHV-6B-T3  
(, ) 
Am-TTTTTTTTTATCCTTGGACCGAACTC,  
M1, M2 
HHV-6B (AF157706), 60481 - 60497 
HHV-7-T3 (, ) Am-TTTTTTTTTGGATACAAACTTTGGAA,  
M1, M2 
HHV-7 (AF037218), 56893 - 56909 
GHHV-7-T3 () Am-TTTTTTTTTCCAGGGTACTATAACACAGA, 
M2 
HHV-7 (AF037218), 56852 - 56871 
T3, oligonucleotide (sense, 9T spacer arm before sequence); Am, amino-link; Acc. no, 
accession number; OP, Original publication in which microarray oligonucleotide was used. 
Microarray ID indicates which oligos were spotted on the same microarray in different OPs (M1: oligos 
on the microarray in  OP; M2: oligos on the microarray in  OP).  
*Do not discriminate the types.  
**Underlined nucleotide A is match for HSV-1. 
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1.6. Microarray reactions  
 
The reagents which differ in different microarray methods (, ) are 
presented in Table 3. Two multiplex-PCR products were pooled before 
transcribing into ssRNA using AmpliScribe™ T3 High Yield Transcription Kit 
(described in , ) and AmpliScribe™ T3 FLASH Transcription Kit () 
(Epicentre, Madison, WI) following the manufacturer’s instructions. Pooled 
multiplex-PCR solution which contained the improved multiplex-PCR1 was 
denaturated for 2 min at 96C before ssRNA transcription at 42C for 1 h 
(). The ssRNA was quickly denatured (95C for 1.5 min) before adding NaCl 
to give final concentration of 1.5 mM, and allowing hybridization for 20 min 
at 42C with oligonucleotides on arrays (Fig. 2).  
 
TABLE 3. Reagents and kits in original publication of  and .  
Reaction/Reagent Reagents or Kit used in OP of  Reagents or Kit used in OP of  
Slides used for 
microarray  
Microscope glass slides activated 
as described by Guo et al. [1994] 
and Pastinen et al. [2000] 
SAL-1-slides (Asper Biotech) 
Oligonucleotide 
spotting buffer 
Sodium carbonate buffer (pH 9.0)  1MSS (ArrayIt, TeleChem 
International, Inc.) 
SsRNA 
transcription 
AmpliScribe™ T3 High Yield 
Transcription Kit (Epicentre) 
AmpliScribe™ T3 FLASH 
Transcription Kit (Epicentre) 
OP, Original publication in which the reagents or kits were used.  
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Fig 2. Herpesvirus-specific 
oligonucleotides were 
spotted on microarray (A.) 
and ssRNA templates 
transcribed from multiplex-
PCR products were 
hybridized to 
oligonucleotides (B.). If 
complete hybridization 
occurs, especially at the 3-
end of oligonucleotides, 
MMLV reverse transcriptase 
can add fluorescently 
labeled nucleotides to the 
ssRNA template (C.) and 
signal can be detected from 
these spots. 
 
Before the extension reaction (20 min at 52C), the microarrays were washed 
with array-washing buffer [0.5TE (5 mM Tris, 0.5 mM EDTA), 0.3 M NaCl 
and 0.1% Triton X-100 (YA Kemia, Helsinki, Finland)] and sterile water (Fig. 
2.) The extension solution, containing 55 mM Tris-HCl, 11 mM MgCl2, 83 
mM KCl, 11 mM DTT (Epicentre), 0.6 M dATP, dGTP, ddATP, ddGTP, dUTP-
CY5 and dCTP-CY5 (Amersham Bioscience, Little Chalfont, UK), 5 U MMLV 
reverse transcriptase (Epicentre), 0.5 M trehalose (Sigma-Aldrich) and 8.3% 
glycerol (MP Biomedicals, Irvine, CA), was added in a final volume of 4.5 l (, 
, ). After the extension reaction, the microarrays were washed with array 
washing buffer and water, and then dried. Microarrays were dipped in 50 
mM NaOH before the final washing step when SAL-1-slides (Asper Biotech) 
were used (). 
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1.7. Analysis  
 
The microarrays were analyzed using a ScanArray Express scanner with 
ScanArrayTM and QuantArrayTM software (PerkinElmer, Wellesley, MA). The 
cut-off value was determined for each subarray separately by calculating the 
mean value of local background-corrected intensities from non-specific 
oligonucleotides. The specific spot intensities were also corrected by 
subtracting local background. Intensities at least three times above the cut-
off value were considered positive.  
 
2. SEROLOGICAL MICROARRAY (V)  
 
2.1. Clinical specimens  
 
For initial testing of the microarray, 61 patient sera were collected from 
patient serum panels previously tested for Puumala hantavirus antibodies at 
HUSLAB (Helsinki, Finland) during 2002. Altogether, 15 out of 61 were IgG-
positive, 30 were IgG- and IgM-positive, one was IgM-positive, and 15 were 
IgG- and IgM-negative.  
 
The herpesvirus study material included 122 serum samples (107 
individuals) sent to HUSLAB (Helsinki, Finland) for analysis of HSV 
antibodies, 134 (118) for VZV antibodies, and 134 (117) for CMV antibodies 
during 2005 and 2006.    
 
2.2. Viral antigens 
 
The Escherichia coli derived recombinant proteins (ProsPec-Tany TechoGene 
Ltd, Rehovot, Israel) contained the CMV pp150 (UL32) immunodominant 
region (1011-1048 amino acids), HSV-1 gG (84-175 amino acids), HSV-2 gG 
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(525-578 amino acids) and VZV gE (amino acids 48-135). The recombinant 
proteins were purified by proprietary chromatographic techniques and a 
purity of >95% was determined by 10% polyacrylamide gel electrophoresis 
(PAGE) according to the manufacturer. Puumala hantavirus nucleocapsid 
protein (PUUV-N) was produced and purified according to Vapalahti et al. 
[1996]. The purity and concentration of PUUV-N were determined by PAGE 
using Precision Plus Protein™ Standards (Bio-Rad Laboratories, Espoo, 
Finland), and by spectrophotometry (280nm).  
 
2.3. Microarray design  
 
The viral antigens PUUV-N, HSV-1 gG-1, HSV-2 gG-2, VZV gE, and CMV 
pp150 (ProsPec-Tany TechoGene Ltd) in dilutions of 0.5-1.0, 0.25-0.50, and 
0.05-0.1 g/l for PUUV-N; 10 and 30 g/l for HSV-1 gG1, HSV-2 gG2 and 
CMV pp150; and 0.1 and 0.3 g/l for VZV gE, were spotted in duplicate on 
nitrocellulose-coated FAST slides (Schleicher and Schuell BioScience Inc., 
Keene, NH) at Biomedicum Genomics (University of Helsinki) using a 
microarrayer (OmniGrid, GeneMachines, Huntingdon, UK). Ten-fold 
dilutions of human IgM and IgG (Sigma-Aldrich Finland) were used as 
positive controls, and rabbit myosin (Sigma-Aldrich, Helsinki, Finland) and 
protein-printing buffer (TeleChem International Inc.) were used as negative 
controls on the microarrays.  
 
2.4. Microarray reactions 
 
After rinsing with PBS, the microarrays were blocked with blocking solution 
[2% bovine serum albumin (BSA, Sigma-Aldrich Finland) in PBS] for 90 min. 
IgG and IgM assays (Fig.3.) were performed in parallel. One microarray 
included 21 arrays, of which four were used for detection of positive- and 
one for negative-control samples.    
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Fig. 3 Herpesvirus-specific antigens were spotted on a 
microarray (A) and a dilution of a human serum sample was 
placed on the microarray. Human antibodies for specific 
herpesviruses attached to their specific antigens (B). 
Attachment was detected by labeled anti-human antibody (C) 
that attached to human antibodies, resulting in a signal at 
antigen specific spots (D).    
 
2.4.1. IgG assays 
 
Serum samples were diluted 1:200 in blocking solution, and 10 l of each 
was transferred to a separate array and incubated for 30 min at room 
temperature. Before the washing steps, which were 3 times 3 min with 
washing buffer [0.2% Tween 20 (Fluka, Sigma-Aldrich Chemie GmbH, Buchs 
SG, Switzerland) in PBS], the serum dilution was removed by rinsing with 
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the washing buffer. The microarrays were rinsed with PBS before incubating 
at room temperature for 15 min with 1 g/mL Alexa 546 -labelled goat anti-
human IgG (Molecular Probes Europe BV, Leiden, The Netherlands) in PBS 
to detect antibodies attached to viral antigens (Fig. 3). Finally, the washing 
steps were repeated followed by a final rinse with sterile water and drying by 
centrifugation for 3 min at 1300 g in 50 ml Falcon tubes.  
 
2.4.2. IgM assays 
 
The protocol for the IgM test was identical to the IgG test with a few 
exceptions. Before dilution of a serum sample, the IgG from the sample was 
inactivated using GullSORB™ (Meridian Diagnostics Inc, Cincinnati, OH). 
One g/ml Alexa 647-labeled goat anti-human IgM (Molecular Probes 
Europe BV) in PBS was used for antibody detection.    
 
2.5. EIA and immunofluorescent assays 
 
Puumala hantavirus IgG and IgM antibodies were previously tested with IFA 
and -capture EIA, respectively [Kallio-Kokko et al. 1998; Vapalahti et al. 
1996]. Briefly, IF assays (IgG) were carried out using the PUUV Sotkamo 
strain grown in Vero E6 cells as an antigen and fluorescein isothiocyanate 
(FITC)-conjugated anti-human-IgG was used to detect the binding of PUUV 
antibodies to antigen. In -capture EIA, the plates were coated with goat 
anti-human IgM for capturing the IgM antibodies from serum samples. The 
specific PUUV-N recombinant protein was added and specific attachment of 
this antigen was detected with peroxidase-conjugated monoclonal antibody, 
which resulted in a visible reaction with substrate.    
 
HerpeSelect® HSV-1 IgG and HSV-2 IgG ELISA kits (Focus Diagnostics Inc, 
Cypress, CA), and the EIAgen HSV IgM test (Adaltis Italia S.p.A., Casalecchio 
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di Reno, Italia) were used for HSV antibody detection. HSV-1 and HSV-2 gG 
were used as antigens for the HerpeSelect® HSV-1 IgG EIA test and HSV-2 
IgG EIA test (Focus Diagnostics Inc). The EIAs were coated with antigen and 
used to capture specific antibodies from serum samples. The captured 
antibodies were detected using peroxidase-conjugated anti-human IgG and 
tetramethylbenzidine (TMB) as substrate for the color reaction. In the EIAgen 
HSV IgM test (Adaltis Italia S.p.A.) the -capture principle was used. In this 
assay, IgM antibodies in the sample are first captured by the solid phase 
coated with anti-human IgM, and then after washing, the specific HSV IgM 
antibodies are detected by the addition of UV-light inactivated HSV-1 and 
HSV-2 particles that are labeled with a specific antibody conjugated to 
horseradish peroxidase (HRP). The substrate is added to reveal the bound 
conjugate, indicating a positive result. A sample dilution of 1:101 was used 
in these EIAs.  
 
VIDAS CMV-IgG and -IgM Kits (bioMérieux sa, Marcy l’Etoile, France) and 
EIAgen Varicella Zoster IgM tests (Adaltis Italia S.p.A.) were used for CMV 
and VZV antibody detection, respectively. On VIDAS CMV-IgG and –IgM tests 
(bioMérieux sa), specific information on the antigen was not provided by 
bioMérieux sa. In both kits, the HCMV antigen was coated onto the solid 
phase and serum antibodies that attached were detected by conjugation and 
a substrate reaction. In the VIDAS system, 100 l of sample was needed to 
perform the IgG test and another 100 l for the IgM test.  
 
In the EIAgen VZV IgM test (Adaltis Italia S.p.A.), the solid phase is coated 
with anti-human IgM, which captures IgM antibodies from the sample. 
Incubation with partially purified VZV which was inactivated by treatment 
with -propiolactone, in a complex with monoclonal antibodies conjugated 
with HRP detects the specifically bound VZV antigen when substrate is 
added. A sample dilution of 1:101 was used in the EIAgen VZV IgM test 
(Adaltis Italia S.p.A.). All herpesvirus EIAs were performed according to the 
manufacturers´ instructions. 
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An accredited in-house sandwich-EIA (HUSLAB, Helsinki University 
Hospital, Helsinki, Finland) with VZV glycoprotein EIA antigen (Institute 
Virion Ltd, Rüschlikon/Zürich, Switzerland) was used for VZV IgG testing. 
The VZV antigen was used for coating and capturing specific antibodies from 
the sample. Anti-human IgG labeled with HRP was used to detect antibodies 
bound to antigens and substrate was used for the color reaction. A sample 
dilution of 1:100 was used in VZV IgG EIA. 
 
2.6. Analysis  
  
Microarrays were analyzed using a ScanArray Express scanner with 
ScanArrayTM and QuantArrayTM software (PerkinElmer, Wellesley, MA). The 
cut-off value was determined separately for each array. Briefly, the spot 
intensity had the local background subtracted, and the cut-off value was 
determined by multiplying at least three times the mean value of intensities 
from negative control spots. Intensities at +/- 10% of the cut-off value were 
considered to give an equivocal result.  
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RESULTS AND DISCUSSION  
 
1. DEVELOPMENT OF MULTIPLEX-PCR AND MICROARRAY 
METHODS 
  
Our aim was to set up an efficient and sensitive multiplex-PCR and 
microarray method for detection of multiple herpesvirus DNAs, especially for 
use in viral DNA detection in CNS infections. At the moment, the diagnostic 
assay of choice in CNS infections is qualitative PCR. CSF samples are 
challenging due to the fact that diagnostic PCR must be able to detect viral 
DNA varying from 2102 to 4107 genome copies per ml in initial samples 
from encephalitis patients [Schloss et al. 2003]. Our results have indicated 
that microarray method is sensitive, and they can become the assay of 
choice for efficient detection of viral DNA from clinical samples.  
 
One of our goals was to apply the developed microarray method to suit 
detection of viral infection in CSF as well as other clinical specimens such as 
serum, plasma and whole-blood. One aim was to optimize the microarray 
method so that it could be applied in diagnostics and would require only a 
single working day for completion. In addition, one of the goals was to use 
the microarrays to detect possible co-infections which may be missed using 
routine laboratory PCR methods. The advantage of microarrays is that they 
can be used to screen viruses from multiple samples simultaneously with 
accuracy and speed. Therefore, our aim was also to test the usefulness of the 
microarray method for detecting various herpesviruses from large series of 
samples.  
 
In brief, in the method developed the viral DNA was amplified using 
multiplex-PCR. The PCR products were transcribed to ssRNAs before 
hybridizing to short oligonucleotides on a microarray followed by primer 
extension with fluorescent nucleotides. Similar methods have been reported 
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previously but not for herpesvirus infections [Pastinen et al. 2000; Riise 
Stensland et al. 2005; Jääskeläinen & Maunula 2006].  
  
1.1. Detection limits of multiplex-PCRs and microarray (, ) 
 
The aim was to amplify 8 herpesviruses in one reaction or under a single set 
of reaction conditions with the goal of detecting 10 or less viral copies or 
particles per reaction. First, the multiplex-PCR and microarray method was 
set up using the primer pair earlier described by Piiparinen & Vaheri [1991] 
as well as primer pairs and oligonucleotides designed specificly for this 
purpose (described in original publication ). However, this primer pair for 
HSVs did not work with all the other primers when commercial viral DNA 
controls were tested and therefore, the HSV amplification had to be carried 
out in a separate reaction to achieve optimal sensitivity. Finally, two 
multiplex-PCRs, one for HSV-1 and HSV-2, and another for VZV, CMV, EBV, 
HHV-6A, HHV-6B, and HHV-7, were optimized so that they could be 
performed in the same reaction conditions and detection limits were 
determined.  
 
The microarray method had good detection limits varying from 1 to 7 viral 
genome copies, or from 2.5 to 9.1 VPs per reaction (Table  and Fig. 1 in 
original publication ). These detection limits indicate a quantity of between 
2.5101 and 1.75102 genome copies of CMV, EBV, HHV-6A or HHV-7, and 
6.25101 to 4.55102 VPs of HSV-1, HSV-2, VZV, or HHV-6B per ml of 
sample. Calculations were based on that DNA was extracted from 200 l of 
sample, eluted in 50 l, of which 5 and 10 l were used as template for 
multiplex-PCR-1 of HSVs and -2 of other herpesviruses, respectively.  
 
With high viral copy numbers, i.e. over ~4106 genome copies per ml, 
accurate herpesvirus identification was achieved with the microarray 
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method. However, some cross-reaction between HHV-6A and HHV-6B 
oligonucleotides was observed when over 10 000 HHV-6B VPs (i.e. 2.5105 
VPs per ml of sample) were added to the multiplex-PCR. At high 
concentrations of HHV-6A DNA, no cross-reactions were observed.  
 
The multiplex-PCR and microarray method () was tested with patient 
samples. Three HSV-positive CSFs were tested, and one of these samples 
remained negative in the microarray while parallel diagnostic PCR gave a 
positive result. When the multiplex-PCR for HSVs was studied more closely, 
it was seen that the microarray was negative although the multiplex-PCR 
product could be visualized by agarose gel electrophoresis. In addition, the 
detection limits for microarray and multiplex-PCR of HSVs by agarose gel 
electrophoresis were the same. The results indicated that the method has to 
be improved for detection of HSVs. For other herpesviruses, the microarray 
was found to be the more sensitive detection method than agarose gel 
electrophoresis. The secondary structure of the HSV-PCR product was 
suspected to block efficient ssRNA production, and therefore effecting to 
results from microarray.  
  
To improve the method, a new primer pair for HSVs, a multiplex-PCR () 
and detection oligonucleotides for the microarray were designed. In addition, 
new detection oligonucleotides () for VZV, CMV, EBV, HHV-6, and HHV-7 
were also designed to increase the number of oligonucleotides for detecting 
possible diverse PCR amplicons. The improved microarray method () 
provided a detection limit of 5 copies per reaction for commercial viral DNA 
of HSV-1 and HSV-2, which in turn indicated 2.5102 genome copies per ml 
of sample. This detection limit was comparable to the limits of 2102 and 
2.3102 genome copies per ml reported by Schloss et al. [2003] and Aberle & 
Puchhammer-Stöckl [2002], respectively. The original method () was also 
retested with serial dilutions parallel with the improved one. However, an 
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accurate determination of detection limits was not successful due to the 
inconsistent results of the ssRNA transcription.  
 
Boriskin et al. [2004] used microarrays to detect 13 different pathogens, 
including HSV-1, HSV-2, VZV, CMV, EBV, HHV-6A, HHV-6B, and HHV-7, 
using long probes consisting of purified multiplex-PCR products on 
microarrays. In addition, Korimbus et al. [2005] developed a microarray for 
detection of HSV-1, HSV-2 and CMV. The sensitivity of the multiplex-PCR 
and microarray method described by Boriskin et al. [2004] was determined 
by using CMV and echovirus as representatives for DNA and RNA viruses, 
respectively. The analytical sensitivities were 46 CMV DNA copies (1 ng) and 
28 echovirus RNA copies (125 ag) per reaction. Korimbus et al. [2005] 
reported a sensitivity of 500 genome equivalents (Geq) per ml of CSF spiked 
with HSV-1, which is ~14 Geq per reaction (calculations based on 
information provided in their article: 100 l of sample was extracted and 
eluted to 100 l, and 27.5 l of template was used in PCR). The sensitivities 
for other herpesviruses were not reported by Boriskin et al. [2004] or 
Korimbus et al. [2005].  
 
These detection limits, including those for our microarray method, are 
directional and cannot be directly compared due to the different viral DNA 
origin and quantifications methods. However, it can be speculated that our 
method is as or more sensitive as these microarray methods. To provide a 
broad field of sensitivity, the detection limits were determined for all 
herpesviruses with our microarray method while Boriskin et al. [2004] and 
Korimbus et al. [2005] reported only for one or two herpesviruses.  
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1.2. Analysis of clinical specimens (, ) 
 
To define the applicability of the microarray method (, ) in clinical 
diagnostics, patient samples were tested and results compared to parallel 
PCR results from daily diagnostics in HUSLAB (Helsinki, Finland). The 
microarray and diagnostic PCR results were compared in a qualitative 
manner.  
 
With the first microarray method (Tables V, V and X in original 
publication ), PCRs and microarrays gave concordant results for 214 out of 
227 (94%) clinical samples. Altogether, there were 161 PCR-negative 
samples, and the microarray method gave a negative result for 154 of them, 
resulting in a specificity of 95.3%. Of 66 PCR-positive samples, the 
microarray method gave a concordant positive result in 62 cases, resulting 
in a sensitivity of 93.9%. Although, good sensitivity and specificity were 
achieved, more well-characterized samples were needed to demonstrate the 
sensitivity of the microarray method for CSF samples, and especially for 
detection of HSV-1 and HSV-2 DNA. 
 
To improve the multiplex-PCR and microarray method, a new HSV-PCR 
procedure () and new oligonucleotides for herpesviruses () were designed. 
Twenty positive and two negative CSF samples for HSV-1, HSV-2, and VZV 
were collected from HUSLAB (Helsinki, Finland) and they were tested in 
parallel with the improved and original methods. The improved method () 
was superior, and concordant results (Table  in original publication ) 
with diagnostic PCR were achieved in all cases (100%). The original method 
() gave concordant result in 50% of cases.  
 
The applicability of the microarray method was tested using plasma, whole-
blood, and QCMD samples, and the method proved to be suitable for 
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herpesvirus detection in these samples (Tables V and V in original 
publication ). When plasma samples were tested, microarrays also detected 
four possible new positives for CMV, EBV, or HHV-6B from diagnostic PCR-
negative samples collected from transplant patients.  
 
Several double and triple infections were detected with the microarray 
method (Table 4). The detected co-infections were studied more closely to 
confirm the suitability of microarray for detection of multiple infections. Two 
samples collected from renal and bone marrow transplant patients were 
observed to have simultaneously CMV and EBV DNA in the plasma based on 
microarray results (Table 3). Both of these patients were seropositive for 
CMV and EBV, and these findings were confirmed by detecting CMV and 
EBV DNA with diagnostic qPCR. Two possible double infections of EBV-HHV-
7 and EBV-CMV were also detected from EBV-positive plasma samples 
(Table 4). These samples were from bone marrow and renal transplant 
patients. The possible EBV-CMV co-infection detected with microarrays was 
discovered from a bone marrow transplant patient who was EBV seropositive 
and had both CMV IgM and IgG antibodies. However, the CMV DNA could 
not be tested due to sample exhaustion. On the other hand, the serological 
background strongly suggested that this CMV DNA finding might be a true 
finding.  
 
The other possible double infections were HHV-6B-EBV and HHV-6B-HHV-7 
from whole blood samples, and VZV-EBV and VZV-HHV-6B from CSF 
samples (Table 4). Earlier studies had shown that the VZV-HHV-6B positive 
patient had intrathecal antibodies against both VZV and HHV-6 in the CSF. 
One double infection of VZV-HHV-6B in a QCMD sample and one possible 
triple infection of HSV-2, HHV-7 and HHV-6B in a CSF sample were found 
by the microarray method (Table 4). The putative triple infection with HSV-2, 
HHV-7 and HHV-6B in CSF had elevated leucocyte (970106 cells/l) and 
erythrocyte (50106 cells/l) counts, normal glucose values and elevated 
protein levels (597 mg/l). The blood cell levels were high and as a microarray 
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being a very sensitive method, latent herpesvirus DNAs may be detected due 
to the high blood cell counts. To establish the latent HHV-6 infection from 
active one, specific mRNA levels could be determined. In addition, Ward et 
al. [2007] have stated that HHV-6 positive CSF samples can be due to the 
HHV-6 integration into chromosome. To further determine this integration 
the CFS sample should tested for HHV-6 DNA level. The determination of 
HHV-6 DNA level in serum should also be confirmed for reason that the 
high-level serum HHV-6 DNA can indicate integration.  
 
TABLE 4. Samples positive for multiple herpesviruses by 
diagnostic PCR or microarray method () 
Diagnostic PCR 
result and number 
of specimens 
Microarray result and number of 
specimens 
1HSV-2 1 HSV-2, HHV-7 and HHV-6B 1 
1VZV/neg* 2/21 VZV and HHV-6B 1 
VZV and EBV 1 
2CMV  2 CMV and EBV  2 
2EBV 
 
2 
 
EBV and CMV 1 
EBV and HHV-7 1 
3HHV-6  
 
4 HHV-6B and EBV 2 
HHV-6B and HHV-7 2 
4VZV 1 VZV and HHV-6B 1 
neg, negative.  
1CSF, 2Plasma, 3Whole blood, 4QCMD specimens.  
*First former result of PCR, then parallel PCR result with 
microarray. 
 
In daily diagnostics, HUSLAB (Helsinki, Finland) does not test for HHV-7 
from clinical samples by PCR. Four specimens that were HHV-7 positive by 
the microarray method were seronegative for HHV-7 at the time of sampling 
and no follow-up samples were available. Therefore, acute infections cannot 
be conclusively ruled out. 
 
Other studies have shown that co-infections could be relatively common in 
CNS infections. Koskiniemi et al. [2001] studied over 3000 patients with 
acute CNS symptoms and observed possible viral findings in 46% of the 
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cases. Overall, of confirmed and probable viral findings (>650), over 30 
double infections of HSV and VZV were detected. Kupila et al. [2006] also 
observed HSV-1 and VZV co-infection from a patient with encephalitis. 
However, in these studies the PCR tests were carried out for HSV-1, HSV-2 
and VZV, but not for other herpesviruses. Double CNS infections by other 
herpesviruses, e.g. HSV, VZV, EBV, CMV, HHV-6 and HHV-7, have also been 
identified [Sugaya et al. 2002; Weinberg et al. 2005].   
 
 
Rapid and simultaneous detection of herpesviruses is important for proper 
drug treatment and efficient patient recovery. The antiviral treatment is 
immediately started if CNS infection is suspected. To achieve efficient patient 
recovery specific antiviral treatment should be administrated as soon as 
possible. Among herpesviruses some drug resistance has occurred and there 
is no mutual antiviral treatment for all herpesviruses, although acyclovir is 
effective for several herpesviruses. To optimize testing time and sensitivity, 
some changes were made to the first microarray method (, ). More efficient 
reagents were used, e.g. for ssRNA transcription, microarray spotting and 
slides. The total time needed for the assay was approximately 5 h, thereby 
providing results within a single working day. The assay consisted of steps 
from sample processing to array scanning, including the DNA extraction 
with the High Viral Nucleic Acid Kit (Roche Diagnostics) (~20-30 min), 
multiplex-PCR amplification (~1.5 h), ssRNA transcription (1.5-2 h), 
hybridization and primer extension reaction on the microarray, scanning 
and analysis (1-1.5 h).  
  
In conclusion, we optimized the microarray method () for herpesvirus DNA 
detection from CSF, plasma, serum and whole-blood and for completion 
within a single day, and therefore it could be considered a candidate for use 
in diagnostics. Confirmed co-infections indicated that the microarray method 
had the potential to be used as a method for detection of multiple infections. 
Of the human herpesviruses, HSV and VZV in particular are often involved 
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in CNS infections and the most severe CNS infection is caused by HSV 
[Whitley 2006; Hanson et al. 2007]. The improved microarray method was 
shown in particular to detect HSV-1, HSV-2, and VZV in CSF samples. The 
advantage of microarray methods is also that numerous different viral DNAs 
can be detected from a small amount of extracted sample. Stöcher et al. 
[2003] developed four different real-time PCRs for detection of five human 
herpesviruses in a single run with the same parameters. These PCR 
reactions were sensitive but needed to be performed separately, increasing 
the amount of extraction needed for parallel testing of several viruses. In 
addition, the relative time and cost for analysis could be higher than using 
the microarray method.  
 
1.3. Facial palsy study group () 
 
The microarray method () was used for screening purposes before it was 
modified and improved. The main goal was to screen 70 CSF samples from 
FP patients and a control group. Kanerva et al. [2007] previously screened 
this same material for HSV, VZV, and HHV-6 DNA by conventional PCR 
methods and found one patient with HHV-6 DNA.  
 
Results are described in more detail in original publication . Briefly, from 
the study group two positive results were obtained. A 13-year-old girl with 
FP and no additional symptoms was found to be positive for HHV-7 DNA, 
and a 33-year-old woman who had given birth two weeks prior to FP was 
found to be simultaneously positive for HHV-6A and -6B DNA in the CSF 
(Table  in original publication ). Four other patients had intensities barely 
below the cut-off level for positivity. From these samples, the microarray 
method the simultaneous presence of HHV-6A and -6B DNA in one sample, 
two samples were positive for HHV-6B DNA, and one sample was positive for 
EBV DNA (Table  in original publication ).  
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The CSF sample reported by Kanerva et al. [2007] to be positive for HHV-6 
was no longer positive by the microarray method (). The reason for this 
discrepant result could be due to degraded DNA as a result from several 
freezing and thawing cycles of sample. The patients with positive or possibly 
positive for HHV-6 by microarray some presented elevated blood cell levels. 
This can have an influence to results as HHV-6 and HHV-7 can alter to 
latent state in leucocytes. In addition to latency, HHV-6 can be found 
integrated into chromosome and therefore HHV-6 positive CSF samples can 
also be due to the integration [Ward et al. 2007]. To establish the latent 
HHV-6 infection from active one, specific mRNA levels could be determined 
[Yoshikawa et al. 2003]. Ward et al. [2007] noted that integrated HHV-6 DNA 
could also be found in other cells than blood cells, even in hair follicles. The 
integrated HHV-6 DNA level can be quantified in CSF and serum. The high-
level serum HHV-6 DNA may indicate integration. Due to the retrospective 
nature of this study, there were no serum samples available and most of the 
CSF samples were exhausted during the study.    
 
 
Our result showed that microarrays are sensitive methods and efficient in 
screening of herpesvirus DNAs in a large panel of samples.   
    
2. SEROLOGICAL MICROARRAY FOR HSV, VZV, AND CMV (V) 
 
The aim of this study was to set up an easy screening tool for herpesvirus 
antibodies. A successful combination of preferred immunological assays on 
one platform and simultaneous detection of several herpesvirus antibodies is 
the goal. A microarray method was considered appropriate for achieving this 
goal and so a serological microarray was designed (V). Briefly, a microarray 
was designed, evaluated and compared to the commercial and in-house 
accredited EIAs used in daily diagnostics by HUSLAB (Helsinki, Finland).  
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The PUUV-N recombinant protein was first immobilized on a microarray for 
single virus antibody detection from previously tested serum samples. The 
results from PUUV IgG and IgM antibody testing gave excellent specificities 
and sensitivities. The specificities were 100% for both PUUV IgG and IgM, 
and the sensitivities were 84.1% and 90.6% for PUUV IgG and IgM, 
respectively. 
 
The high level of purity of recombinant proteins was found to be essential for 
accurate screening. Therefore, a serological microarray for HSV-1, HSV-2, 
VZV, and CMV antibodies was set up using commercial high-purity 
recombinant proteins and tested with patient samples. The HSV G 
glycoproteins gG1 for HSV-1 and gG2 for HSV-2, which have been used in 
serological assays to distinguish between HSV-1 and HSV-2, were used as 
antigens for HSVs in microarrays [Ashley 2002, Ashley et al. 1998, Wald, 
Ashley-Morrow 2002]. VZV gE, which has been found to be efficiently 
recognized by the immune system, and CMV pp150, a protein of viral 
tegument that has been found to be highly immunogenic, were immobilized 
on the microarray [Fields BN, Knipe DM & Howley PM 1996; La Rosa et al. 
2005, Landini et al. 1991].  
  
The specificities for HSV-1, HSV-2, VZV and CMV IgG were 75.9%, 94.7%, 
82.6%, 81.4%, respectively (Table 5). The specificity of HSV-1 IgG was below 
80% because the microarray method detected 14 new positives for HSV-1 
IgG out of 58 negative with EIA. Of these 14, five had HSV IgM antibodies as 
determined by EIA, which may indicate that microarray detected possible 
IgG antibodies earlier than commercial EIA. The sensitivities for HSV-1, 
HSV-2, VZV and CMV IgG were 93.3%, 65.2%, 76.1%, and 83.0%, 
respectively (Table 5). These sensitivities, except for HSV-2, could be 
considered to be good.  
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TABLE 5.  Results from herpesvirus-specific EIAs compared to microarrays, and calculated 
diagnostic specificities and sensitivities. 
 
Herpesvirus EIA, no 
of samples 
 
MICROARRAY Results 
G+  G- E DSP DSN  
HSV-1 G+  49 44 4 1 75.9% 93.3% HSV-1 IgG 
HSV-2 G+ 10 5 5 - 
HSV-1, and -
2 G+ 
13 13 of which 9* double 
and 3 HSV-1 pos,  
1 HSV-2 pos 
- - 94.7% 65.2% HSV-2 IgG 
HSV-1 G-  58 14 44 - 
HSV-2 G- 95 5 90 - 
 M+   M- E DSP DSN  
HSV M+ 15 4 11 - 95.9% 26.7% HSV IgM 
HSV M- 98 4 94 - 
HSV M E 1  1  
 G+  G- E DSP DSN  
VZV G+  110 89 18 3 82.6% 76.1% VZV IgG 
VZV G- 23 4 19 - 
 M+   M- E DSP DSN  
VZV M+ 58 46 6 6 43.5% 88.5% VZV IgM 
VZV M- 69 39 30 - 
VZV M E 6 2 2 2 
 G+  G- E DSP DSN  
CMV G+  91 73 15 3 81.4% 83.0% CMV IgG 
CMV G- 43 8 35 - 
 M+   M- E DSP DSN  
CMV M+ 14 12 2 - 99.1% 85.7% CMV IgM 
CMV M- 118 1 113 4 
CMV M E 2  2 - 
G, IgG; M, IgM, E, equivocal; +, positive; -, negative; DSP, diagnostic specificity; DSN, 
diagnostic sensitivity. 
 
*Nine samples had dual antibodies against HSV-1 and -2.   
 
Good specificities for HSV and CMV IgM (95.9% and 99.1%, respectively) 
were achieved but the specificity for VZV IgM was only 43.5% (Table 5). 
Sixty-nine samples were VZV-IgM negative by immunoassay but 39 of these 
samples were positive according to the microarray. However, 31 out of the 39 
samples had high levels of VZV-IgG antibodies, and it could be speculated 
that the false positives might be due to IgG adsorbing before IgM in the 
microarray. Sensitivities of the microarray method for HSV, VZV and CMV 
IgM varied being 26.7%, 88.5%, and 85.7%, respectively (Table 5).  
 
The EIA for HSV IgM detection used in HUSLAB (Helsinki, Finland) does not 
differentiate the HSV-1 and HSV-2 IgM antibodies. With the microarray, 
HSV-1 and HSV-2 antibodies were both detected, and differentiation was 
achieved when IgG antibodies for both were present in the sample. The 
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sensitivity of the HSV-2 IgG was only 65.2% with the microarray. The lower 
sensitivity of HSV IgM could be due to a failure to properly detect that the 
sample was positive for HSV-2 IgM. According to the manufacturer (Prospec-
Tany Technogene Ltd.), the recombinant protein was immunoreactive with 
sera of HSV-infected individuals. However, the recombinant protein can be 
denaturated during microarray spotting and storage, thereby losing some of 
its activity and ability to bind specific antibody. One possibility could also be 
that glycoprotein G is not the best possible antigen for efficient antibody 
detection due to the gG deficient HSV-2 strains [Nordberg et al. 2007]. At the 
moment, the commercial kits contain other antigens such as UV-light 
inactivated HSV-1 and HSV-2 particles, which are used in HSV IgM tests 
(Adaltis Italia S.p.A).  
 
The sensitivities and specificities of our assay were promising, but some 
optimization is still needed to achieve a reliable serological tool for diagnosis. 
However, this microarray method might be used as a fast screening test for 
detection of IgG antibodies to HSV-1, VZV and CMV, in order to provide an 
immunological history. The herpesvirus-specific EIAs are often quantitative 
assays and used to monitor antibody levels of sample. Accurate EIAs are 
commercially available, but when used as a screening tool they could be 
laborious, expensive and sample-consuming. Some specific EIAs even need 
100 l of sample, e.g. the VIDAS-system (bioMérieux sa) for CMV antibody 
detection. The microarray method uses sample efficiently, and only 1 l is 
needed for simultaneous detection of different antibodies. Microarrays 
cannot not yet be considered a highly reliable quantitative method, although 
some published studies of viral antibody detection have been carried out [Lu 
et al. 2005; Mezzasoma et al. 2002]. However, as a screening tool, the 
microarray could be a superior method. After screening, some of the results 
can be confirmed by specific EIA to reveal quantitative antibody levels for 
diagnosis of acute infections. This could potentially reduce the amount of 
expensive EIAs used in daily diagnostics. 
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CONCLUDING REMARKS AND FUTURE PROSPECTS 
 
Microarray methods have the potential to replace some of the assays used in 
diagnostics. For example, the multiplex-PCR and microarray method () 
developed for detection of eight human herpesviruses can be further 
modified to be used in daily diagnostics of CNS infections. Sequential PCRs 
can be replaced with one microarray test. The microarray method is a 
qualitative assay, at least for now. However, microarrays can be used as 
screening tools in other than CNS infections, e.g. for CMV and EBV DNA 
detection from transplant patient samples, after which quantitative PCRs 
could be carried out on the microarray-positive samples. Therefore, fewer 
quantitative PCRs can be carried out, and in potential multi-infections, 
quantification can be performed for all the microarray-screened viruses with 
quantitative PCR. Serological microarrays could be used as a fast screening 
tool. In the future, when microarray technology has evolved and been tested 
more, perhaps serological assays such as EIAs could be replaced by 
microarrays. Developing of spotting equipments and reagents is proceeding, 
and reproducibility can be achieved faster.  
 
In conclusion, microarray-based methods have showed the potential to be an 
efficient diagnostic assay. In the future, it is likely that the technique will be 
further developed to meet the requirements of routine diagnosis of viral 
infections.  
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